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CHAPTER! 
1.1. General Introduction. 
In radiotherapy of pelvic cancers, the X-ray dose to be delivered to the tumour is 
limited by the tolerance of healthy surrounding tissue. In the past, with orthovoltage 
equipment, skin tolerance was the main limiting factor. With the introduction of 
megavoltage equipment, it became possible to deliver a higher radiation dose to 
deep-seated lesions, but inevitably also to neighbouring normal tissues. As a result, 
local cure rates were increased, but so was the number of complications. 
In recent years we encountered a number of serious complications of irradiation of 
pelvic organs. It was in particular in cases of ovarian cancer where a higher dose of 
irradiation was applied that these distressing complications were frequent. This ex-
perience led to a more conservative irradiation protocol in these cases, resulting in a 
marked fall in the number of complications. In cervical and endometrial cancer the 
damage never was as extensive as in the ovarian cancer group. At present many 
patients who have to ondergo pelvic irradiation, however, will have transient or 
longer lasting symptoms caused by the irradiation. 
Modern radiotherapy necessitates the acceptance of a calculated risk of complica-
tions in order to achieve a better cure rate. To calculate these risks, one has to know 
the radiation dose-effect relationship of normal tissues. In quantitative terms these 
risks are insufficiently known. The normal tissues most at risk when treating pelvic 
tumours are the bladder, the ureters, the rectum, the sigmoid colon and the small in-
testine. 
In this study we limit ourselves to the bowel. 
The literature regarding postirradiation bowel complications is very confusing. In 
the first place no two authors used the same criteria for what they consider to be 
bowel complications. Some authors only include severe complications like stenoses 
of the bowel and fistulas, in particular those that require surgical intervention (5, 8). 
Other authors include patients with diarrhea and/ or malabsorption, whereas a third 
group will include ill defined situations that necessitate long-term hospitalization. 
It is clear that in this way severe and mild complications are often mixed. The result 
is that in different series the incidence of severe gastro-intestinal complications 
varies as much as from I to 15"7o (l-12).lt is to be noted that in these studies damage 
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to the small intestine form only a minority. Another drawback of the reported stud-
ies is that all were retrospective. In addition when patients appear to have a recur-
rence of their tumour in parallel with radiation damage, they are often excluded 
from further evaluation. 
In view of the rarity of the severe postirradiation bowel syndromes, a prospective 
study of these complications would require a very large number of patients. This 
type of study has never been undertaken. 
This does not mean that the incidence of fistulas and stenoses in irradiation of uter-
ine cancer is negligible (in our own institute we found 6"7o, unpublished data, 
Tj. Kuipers), but only that a prospective study is not feasible. 
Newman (13) reported that in the follow-up of a group of patients, irradiated for 
pelvic tumours, the incidence of a change in bowel habits was substantial. 
The high incidence of relatively mild bowel symptoms would make a prospective 
study with special attention to the incidence and course of these symptoms worth-
while. 
Therefore, we studied diarrhea, either transient or lasting. It is more frequent and is 
possibly a reflection of the pathophysiological changes in the small intestine. 
In a study of 15 patients with postradiotherapy diarrhea, Van Blankenstein (84) re-
ported that all had frequent and loose bowel movements and feacal incontinence, 
despite a relatively low daily faecal weight. All had abnormal bile acid reabsorption. 
On the basic of these preliminary studies, two types of intestinal radiation damage 
were suggested (84): 
I) Patients with clinical symptoms of fistulas, stenoses, (sub)ileus, malabsorption 
and weight loss and rarely perforations. These are the patients with severe 
gastrointestinal complications of radiotherapy. 
2) Patients with diarrhea, faecal incontinence but no weight loss. These are patients 
with relatively mild complications of radiotherapy (mild radiation enteropathy). 
In the present investigation we concentrated on this second group of patients with 
relatively mild symptoms. We studied the incidence and course of postirradiation 
diarrhea in 196 patients treated for carcinoma of the uterine cervix or endometrium. 
Another matter where confusion reigns in the literature is the mechanism of post-
irradiation diarrhea (54, 63, 64, 84). 
Most authors consider insufficient reabsorption of bile acids as the cause. This is by 
no means certain and local factors in the rectosigmoid e.g. a decreased reservoir 
function should be studied as well, in particular in view of the normal faecal weight. 
At the time our study was started, no data were available on this subject. Recent 
work (82, 93) underlined the role of a damaged reservoir function. 
The aims of the present study were: 
I) to determine the incidence, course and prognostic signifiance of postirradiation 
diarrhea; 
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2) to assess the influence of radiotherapy factors; 
3) to study the relation of bile acid metabolism to postirradiation diarrhea; 
4) to investigate whether local factors (reservoir function) were primarily respon-
sible. 
In order to investigate whether factors related to the patients or the mode of treat-
ment influenced the occurrence of side-effects a system of "risk factors" is men-
tioned in the literature (14, 15, 16, 18). 
1.2. Risk factors for bowel damage following radiotherapy. 
Factors that are assumed to influence the incidence of bowel complications can be 
divided into two groups: 
I) Patient factors, these are characteristics of each individual patient, due either 
to somatotype or medical antecedents. These factors cannot be influenced. 
2) Treatment factors, these are related to therapeutic measures which may be 
changed if necessary. 
Many observations concerning these factors have been presented throughout the 
literature, often confusing or even contradictory. This may be due to differences in 
the mode of treatment, but in the majority, to differences in the way complications 
were defined. Most of the studies were retrospective and concentrated on those 
patients who actually did develop severe complications, omitting the rest of the 
patient population. Selection of patients cannot be avoided in this way, making 
comparison between different studies impossible. 
1.2.1. Patient factors. 
We will discuss the following "patient factors": 
I) age; 
2) height and weight; 
3) central abdominal anterior-posterior (AP) diameter; 
4) number of previous laparotomies; 
5) presence of diabetes; 
6) presence of hypertension or cardiovascular disease. 
ad I) For most authors (7, 9, 14, 15), age seemed to be of less importance. Green 
(16), however, suggested that the amount of small intestine in the pelvic 
region tended to be greater in the elderly. 
ad 2) Overweight (as estimated by height and weight) may influence the incidence 
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of complications. Maruyama (7) reported no bowel complications in irradia-
ted overweight patients, 4.50Jo bowel complications in the normal weight and 
13.3% in the underweight group. If diabetes plus hypertension were associ-
ated with underweight, severe bowel damage was even more frequent. 
ad 3) The central abdominal anterior-posterior (AP) diameter is strongly correlated 
with body weight. Polish (14) and Maruyama (7) stated that patients with a 
small AP diameter were more likely to develop complications. They did not ex-
plain why. Green (16) observed that these patients have more immobile small 
intestine in the pouch of Douglas. This pouch is also deeper in patients with a 
small AP diameter. 
ad 4) The number of previous laparotomies is thought by all authors (2, 9, 10, 14, 
15, 17, 18) to be of major importance. Their explanation is that under normal 
circumstances the mobility of the small intestine enables it to move in and out 
of the treatment area. In doing so, the dose of radiation absorbed by the individ-
ual gut segment is reduced. Whereas it is wellknown that previous pelvic 
irradiation in itself will cause intestinal adhesions, some authors (14, 18) claim 
that previous operations in any part of the abdomen will augment the inciden-
ce of severe postirradiation complications. A fact that they ascribe to postoper-
ative rather than postirradiation adhesions of the small bowel. An increased 
incidence of rectal and rectosigmoid complications after previous abdominal 
surgery in these patients is also reported. 
ad 5) Diabetes is supposed to be of poor prognostic significance (7, 14, 15, 19). 
Maruyama reported an increased incidence of radiation induced bowel com-
plications in diabetics. His study concerned only a small number of patients. 
In the group of diabetics, radiation sequellae were found mainly in associ-
ation with underweight and hypertension. 
ad 6) The probability of complications is reported by Potish (14) to be significantly 
related with hypertension. 
According to some authors (7, 14, 15) the common denominator of these six factors 
is supposed to be pre-existent vascular changes. As the underlying cause of late 
radiation damage is of vascular origin, pre-existent vascular changes were assumed 
to be unfavourable. 
Many of these factors have been evaluated independently; however, they may be 
interrelated. Therefore, a multivariate statistical analysis of all of these factors with 
respect to small bowel side-effects and late complications is important in order to 
establish the prognostic value of each factor alone ore in combination with others. 
Radiation related factors which are mentioned in the literature will be discussed 
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next. In addition these factors give some insight in the theoretical background of 
pelvic irradiation. 
1.2.2. Treatment factors mentioned in the literature are: 
I) total delivered radiation dose; 
2) overall treatment time; 
3) fraction dose; 
4) treatment volume; 
5) treatment position; 
6) radiation quality. 
Apart from these characteristics of external irradiation, other factors are important 
in the case of intracavitary treatment. These include: 
T) dose rate; 
8) methods for dose specification. 
ad I) Total dose. Strockbine (2) found that the number of complications increased 
with increasing doses of whole pelvis irradiation. The frequency of sigmoid-
itis, diagnosed on clinical symptoms, roentgenological and proctosigmoidal 
examinations, at dose levels of 40, 50, 60 and 70 Gy was 5, 10.5, 16 and 
3!.50Jo, respectively. 
A problem is that the higher doses of external irradiation were given to 
patients with more advanced disease and these patients also received a higher 
dose from intracavitary treatment. It is not clear from Strockbine's results 
whether these external and intracavitary treatments were evaluated separately. 
ad 2) The influence of overall treatment time on the complication rate has been 
studied with split course treatments (26). Such extension of treatment time 
failed to prevent severe intestinal complications. 
ad 3) The influence of fraction size was investigated by Singh (27), who compared a 
conventional and a reduced frequency schedule. 
Decreasing the number of fractions while increasing their size did not result in 
a change in the incidence of early reactions. However, all patients in the 
reduced frequency schedule developed severe late complications. The overall 
treatment time in both groups was about the same. 
ad 4) A relation between the treatment volume (tissue volume irradiated) and com-
' plications is suggested by many authors (II, 15, 16, 17). It should be realized, 
however, that the amount of small intestine in a given treatment volume is 
highly variable. Therefore, the relation between treatment volume and com-
plications will not be a simple one. It is conceivable that the complication rate 
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is correlated with the volume of the small bowel within the treatment volume, 
but this volume is very difficult to assess. 
ad 5) By changing the treatment position of the patients Green (16) and Caspers 
(29) reported that the volume of small intestine within the treatment volume 
could be decreased. The prone instead of the supine position lifted the lower 
margin of the small intestinal mass 2 em in cranial direction. It can be 
assumed that a change in treatment position during intracavitary irradiation 
will have the same effect as during external irradiation. 
ad 6) With different radiation qualities, the dose distribution within the patient will 
not be the same. With increasing photon energies, the penetration of the radi-
ation becomes deeper. In a thin patient, lower energies like 60Co gamma rays 
and 4 MeV photons are able to give a rather homogeneous dose distribution; 
this will not be the case in obese patients. Higher energies are required to give 
a homogeneous dose distribution in these obese patients. On this point no 
relevant data can be found in the literature. 
ad 7) Dose rate. In fractionated external irradiation, the overall time and the dose 
per fraction causes a more complicated dose-effect relation than in intracavi-
tary irradiation, where the total dose is directly proportional to the dose rate. 
Gray and Kottrneier (I) observed an increased number of rectal complications 
when they shortened the treatment time by using higher activities in the 
intrauterine applicator. What they did, in fact, was to change the dose rate 
without changing the total dose. 
ad 8) The methods for dose specification are very important factors in intracavitary 
treatment, but still controversial. Many different ways of describing the given 
dose are found. Fletcher (30) used the system if milligram hours, where the 
milligrams stand for the amount of radium in milligrams used and the hours 
for the treatment time. The second method, presently applied in the Rotter-
damsch Radio-Therapeutisch Instituut, is the use of "point A", which is a 
virtual anatomical point situated 2 em cranially of the lateral fornix and 2 em 
laterally of the uterine axis (32), (see figure 4, page 40). Because of the steep 
dose gradient around radioactive sources, the choice of reference points for 
dose prescriptions greatly influences the dose in a given site. The third method 
is the use of a reference isodose. A reference isodose is a tridimensional 
contour around the source(s), in all points of which the absorbed dose is 
identical and where the dose applied is specified. 
It is very difficult to get a clear picture from the literature of the importance of these 
factors separately. The range of total delivered dose and dose per fraction presently 
used for pelvic irradiation of gynaecological tumours is quite small (a total dose of 
40-50 Gy over a 4-5 week period with a dose per fraction in the order of 2.0 Gy). 
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This means that no dose-effect relationship can be found; in other words, the influ-
ence of a variable X-ray dose on tissue (bowel) damage cannot be assessed, as the 
variation in dose of external irradiation is too smalL 
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CHAPTER II 
CHANGES IN BOWEL FUNCTIONS FOLLOWING 
RADIOTHERAPY. 
2.1. Historical review. 
Walsh (36) in 1897, two years after Rontgen's dicovery, was the first to report on 
the effects of irradiation on the gastrointestinal tract. Since then, there have been 
many reports on this subject, both from the histopathological and from the point of 
view of intestinal function. 
2.1.1. Histopathology. 
In 1942 Friedman (37) and later in 1966 Trier (38) published excellent studies on 
histological changes of the intestinal wall after irradiation. Both authors observed a 
rapid decrease in the number of mitoses, especially in the mucosa. At about two 
weeks after the start of the irradiation, the villi became shorter and the mucosal 
lining stretched out. Ulcerations eventually developed, sometimes penetrating into 
the serosa. 
The severity of these lesions and the rapidity with which they developed were pro-
portional to the tissue dose. Trier (38) demonstrated by electron microscopy intra-
cellular changes in the lining cells of the villi, e.g., shortened microvilli, swelling of 
the mitochondria and of the endoplasmic reticulum as well as nuclear changes. 
According to Trier, the histology returned to normal two weeks after a course of 
30 Gy. 
2.1.2. Bowel function. 
The most important functions of the small intestine are absorption and propulsion. 
2.1.2.1. Absorption. 
As early as 1924, Dodds and Webster (39) observed increased excretion of fat in the 
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faeces in patients undergoing abdominal pelvic irradiation. Martin (40) reported 
similar findings in dogs. 
After the introduction of isotope investigations (mainly substances labeled with 
!lJI), Reeves (41, 42) reported a transient decrease in fat absorption in patients after 
abdominal irradiation with orthovo1tage equipment (1959) and with 60Co (1963). 
Meanwhile, the first patient with malabsorption following pelvic abdominal radio-
therapy was described by Salvesan (43). This patient had a stricture of the small 
intestine, combined with steatorrhea. On the basis of a review of the literature (5 
patients) and six of their own patients, Duncan and Leonard (44) reported on a 
syndrome of diarrhea. wasting, steatorrhea, intestinal obstruction and anaemia. 
Steatorrhea occurred in 10 out of II patients, diarrhea in 9/11, intestinal obstruction 
in 6/11 and vitamin Bl2 malabsorption in 3/1 I. 
From studies in animals, evidence was obtained that, although fat is mainly ab-
sorbed in the proximal small intestine, fat malabsorption is more pronounced after 
resection of the terminal ileum. This pointed to a role of bile acids in fat absorption 
and will be discussed in more detail later (Par. 2.3.). 
2.1.2.2. Propulsion. 
Both Wallace and Conard (45, 46) studied gut motility with barium meals after irra-
diation, the former in patients and the latter in rats. Wallace described decreased 
motility, whereas Conard found an initial increase followed by a slow return to nor-
mal. 
However, studying intestinal motility by means of barium meals is no longer regard-
ed as a reliable method. Results obtained with dyes and with fluid or solid markers 
differ considerably from each other. Cummings (47) observed more precise results 
by calculating mean intestinal transit time with solid radioopaque markers. More re-
cently, specific motility studies have been performed by analysis of the migrating 
motor complex (48). 
2.2. Diarrhea following radiotherapy. 
During irradiation of the pelvic region, most patients complain about diarrhea. It 
should be noted that for different persons the word diarrhea has a different mean-
ing. When diarrhea is defmed as a loss of the normal consistency of the stools. The 
time of appearance and the severity of the diarrhea are dependent on the fraction-
ation schedule used. With a conventional irradiation schedule of 4-5 times 2.0 Gy 
per week during 5 weeks, these complaints generally develop from the second week 
onwards. After completion of the irradiation, in most cases, the diarrhea subsides 
within a few weeks (86). Few data are available on the number of patients in whom 
the diarrhea does not subside or does even reappear. 
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Newman (13) reported changes in bowel habits in 12 out of 17 unselected patients, 
who received radiotherapy for a gynaecological malignancy. In his clinical study, 
Van Blankenstein (84) reported the combination of diarrhea and faecal inconti-
nence. This observation is in agreement with the observations of Read (81), who 
found that diarrhea from any cause associated with faecal incontinence caused 
problems, whereas diarrhea without faecal incontinence was less troublesome. 
Animal experiments and clinical studies suggested a relation between diarrhea 
following radiotherapy and bile acid metabolism. 
Stryker ( 63, 64) reported an abnormal bile acid breath test as weU as a decrease in 
serum bile acid concentrations at the end of an irradiation period. He found no 
quantitative relation between the observed change in bile acid concentrations and 
the severity of the diarrhea in this smaU, (n = 17) group of patients. 
Van Blankenstein (84) found impaired bile acid reabsorption in aU patients. His 
findings suggested that further study of bile acid metabolism in relation to 
clinical symptoms might be worthwhile. 
2.3. Physiology of bile acids. 
Bile acids are synthesized by the liver. The most important are cholic acid and cheno-
deoxycholic acid. These two are known as primary bile acids; the former is a 
trihydroxy-, the latter a dihydroxy bile acid. The bile acids are conjugated in the 
liver with either glycine or taurine. They are subsequently excreted with the bile and 
stored and concentrated in the gaU bladder. Food intake stimulates gastrointestinal 
hormones, which in tum cause the gall bladder to empty its contents into the small 
intestine. Here, the detergent action of bile acids is involved in micelle formation 
and plays an important role in the absorption of fat and fat-soluble substances. The 
bile acids are reabsorbed from the terminal ileum and returned to the liver by the 
portal venous system. This cycle, is repeated about six times a day and is called the 
enterohepatic circulation (EHC) of bile acids. This cycle (Figure I) is very efficient. 
In healthy persons, no more than about 2"7o of the bile acid pool is lost in the stools 
with each cycle. 
A minor portion of the bile acids is deconjugated and then dehydroxylated by bac-
teria in the colon or terminal ileum, resulting in the formation of secondary bile acids 
(deoxycholic acid and lithocholic acid). Lithocholic acid is insoluble at physiological 
pH of the colon contents and will be almost entirely lost with the faeces. Deoxycho-
lic acid is reabsorbed, mainly in the colon, conjugated and recycled like the primary 
bile acids, forming a substantial part of the bile acids secreted by the liver. 
In 1936, Verzar (49) published his classic study on absorption from the intestine. He 
found that bile acids combine with the fatty acids (which result from lipolysis) to 
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Fig. 1; Schematic representation of the enterohepatic circulation. 
form soluble complexes (micelles). At that time, he still believed the bile acids and 
the fat to be absorbed together. 
Tappeiner's (50) data, confirmed by Baker and Searle (51), indicated that the bile 
acids, in contrast to other water soluble substances, are poorly reabsorbed from the 
jejunum but rapidly from the ileum. Lack and Weiner (52) clearly demonstrated the 
specific and active role of the ileum in this bile acid reabsorption. 
In 1968, Dietschy (53) reviewed the mechanism of intestinal reabsorption of bile 
acids. In principle, bile acids can be present in the intestinal lumen as free or as con-
jugated bile acids; under normal conditions, all bile acids are conjugated. Above a 
certain concentration, which differs for each bile acid, they will form micelles. 
These micelles enable fat soluble substances like fatty acids and cholesterol to 
remain emulsified in the watery environment of the intestine. The bile acids may be 
seen as a constant stream of detergent running through the small bowel. 
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Bile acid transport across the intestinal wall can be either active or passive. As men-
tioned above, in the ileum it is active. 
Nowhere in the small intestine, except for the terminal ileum, are bile acids absorbed 
against a concentration gradient. The efficiency of this transport mechanism was 
not the same for all bile acids; the trihydroxy bile acid cholic acid was more ef-
ficiently reabsorbed than were the dihydroxy compounds deoxycholic and cheno-
deoxycholic acid. Tauroconjugates more rapidly than glycoconjugates (53). In 
contrast to this active process, nonspecific passive absorption of bile acids can take 
place in the small and large intestine. This process is of some importance only for 
the nonionic forms of the bile acids and is therefore mainly confined to the noncon-
jugated forms. Passive absorption of ionized bile acids is dependent on the chemico-
physical properties of the bile acid involved (e.g., number of -OH groups), but is 
quantitatively not very important (53). 
The environmental conditions such as pH, temperature and concentration of 
counter-ions also have an influence. Measurements show that, in passive absorption 
(diffusion) of ionized bile acids, dihydroxy acids are better absorbed than the trihy-
droxy forms and glycoconjugates better than tauroconjugates (53). 
The quantitative significance of extraileal absorption is not precisely known, but it 
certainly is not negligible, as can be concluded from the presence in bile of dihy-
droxy bile acids originating from passive absorption in the large intestine. It should 
be borne in mind, however, that the fact that a certain bile acid can be absorbed 
under experimental conditions does not necessarily prove that this will also happen 
in healthy persons or under pathological conditions (87). 
2.4. Serum bile acids. 
The normal serum level of bile acids is very low. This is due to their efficient extrac-
tion by the liver from both portal venous and arterial blood. This extraction is 70-
90"7o, depending on the bile acid concerned. Among patients, there is a wide vari-
ation in extraction for any given single bile acid. The systemic venous serum level is 
the result of the input into the portal venous system and the extraction by the liver. 
This input is directly related to the reabsorption from the gut. According to LaRusso 
et a! (56), the hepatic bile acid clearance in a patient remains constant and is not 
influenced by portal serum levels. If this assumption is correct, fasting and post-
prandial serum bile acid level determinations would provide a reliable estimate of 
bile acid reabsorption. 
The ratio between the individual bile acid concentrations (cholic versus chenodeoxy-
cholic versus deoxycholic acid) is estimated to be 40 - 40 - 20"7o in bile, 40 - 30 - 30"7o 
in portal venous blood and 15 - 45 - 40"7o in systemic venous blood (57). This indi-
cates that each bile acid has its own specific rate of intestinal reabsorption and 
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hepatic clearance. As a consequence, a change in these concentration ratios in the 
bile, as seen after ileectomy, ileal disease or the blind loop syndrome, will result in a 
change in serum levels of total bile acids. 
LaRusso et a! (56), Schalm et a! (58) and Hepner et a! (59) demonstrated a distinct 
diurnal pattern for the serum concentrations of each of the individual bile acids, 
cholic, chenodeoxycholic and deoxycholic acid. Each bile acid had its own character-
istics of postprandial increase and return to fasting levels. The differences in the 
time at which the postprandial peaks were observed were due to differences in the 
mechanism and site of reabsorption. 
In patients with malabsorption due to ileal disease or ileectomy, postprandial serum 
levels were lower. Throughout the day, they remained relatively constant for cheno-
deoxycholic acid, while they gradually diminished for cholic acid. This is consistent 
with depletion of the cho!yl, but not the cherry! pool (58). This different effect on 
both primary bile acids might be explained by the better proximal reabsorption of 
chenodeoxycholic acid. The cholic acid synthesized during the night, however, is 
ahnost completely lost after the first passage through the small intestine. 
In conclusion, systemic serum total bile acid levels are: 
I) the result of the portal input (reabsorption) and hepatic extraction; 
2) related to the relative proportion of individual bile acids in the bile; 
3) dependent on the time of the day, in relation to meals. 
2.5. Methods for analysing the entero hepatic circulation of bile acids (a review of 
the literature). 
The enterohepatic circulation can be investigated at several levels, as shown in the 
schematic representation (Figure I, page 22); 
I) the duodenal level, where the bile from the gall bladder is introduced; 
2) the level of the ileum, where active reabsorption takes place; 
3) in peripheral venous blood. This is a reflection of the spillover of bile acids 
returned to the liver by the portal venous blood. 
The following methods are mentioned. 
2.5.1. Isotope dilution technique. 
With the isotope dillution technique as described by Lindstedt (70) and Hoffman 
(71), labeled bile acids, I4C cholic acid and I4C chenodeoxycholic acid are adminis-
tered orally or intravenously. The labeled bile acids will mix with the endogenous bile 
acid pool. Duodenal bile samples are obtained by duodenal intubation. A steady 
state is assumed. The slope of the line when plotted logarithmically represents the 
fractional turnover rate of the administered bile acid. The isotope dilution technique, 
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therefore, makes possible the determination of several parameters of bile acid 
metabolism: 
I) cholic and chenodeoxycholic acid pool size; 
2) daily fractional turnover rates of the two primary bile acids; 
3) daily synthesis rates of the two primary bile acids. 
2.5.2. Direct measurement of the loss of bile acids. 
A decreased reabsorption of bile acids at the ileal level results in spillover to the 
colon. There, deconjugation and dehydroxylation take place and even some passive 
absorption. The amount recovered from the stools nevertheless is a good approxi-
mation of this ileal spillover. 
2.5.2.1. The amount of bile acids in 24-hour stools can be determined chemically. If 
there is a steady state, it is a reflection of the bile acid synthesis, as the amount syn-
thesized equalise the amount lost. High faecal levels indicate bile acid malabsorp-
tion (91). 
2.5.2.2. Faecal excretion of a labeled bile acid (labeled within the steroid moiety of 
the bile acid) can be determined. The biological half-life can be calculated by count-
ing the daily excretion of the tracer (62). 
2.5.2.3. The I4C cholylglycine breath test. 
The test is based on the knowledge that under biological conditions only bacteria 
can deconjugate bile acids and that the amino acid released is metabolised and 
partly exhaled as C02• 
In the cholyl-l-I4C-glycine the I4C label is in the carboxyl carbon atom of the glycine 
moiety. The amide bond is rapidly cleaved by bacterial enzymes. After the cleavage, 
the free I4C-glycine is metabolized and I4C02 is released. Abnormal exposure to de-
conjugating bacteria can take place either in the small intestine as a result of proxi-
mal intestinal bacterial overgrowth or in the colon following bile acid malabsorption 
(72). 
A tracer dose of I4C cholylglycine is given in a testmeal. It mixes with the 
endogenous cholylglycine pool. In the case of excessive deconjugation, increased 
amounts of I4C02 will appear in the breath. At given time intervals after ingestion 
of the tracer, the patient blows expiratory air into a vial containing a measured 
volume of an organic base and an indicator that signals the trapping of a 
definite amount of C02• The vial is placed in a liquid scintillation counter and the 
I4C02 specific activity is determined. 
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2.5.3. Detennining bile acid concentrations in the blood serum. 
Serum concentrations of individual and total bile acids can be determined by several 
methods. 
2.5.3.1. Gas chromatography is an accurate method for determining individual bile 
acids in a mixture. The sensitivity is moderate to high, depending on the method 
used. A disadvantage of the method is that no information concerning the conjuga-
tion with taurine or glycine is obtained. With high pressure liquid chromatography, 
the several conjugates can be separated. The sensitivity, however, is rather low and 
therefore the method is not suitable for serum (95). 
2.5.3.2. Generally, a radioimmuneassay can only determine a specific bile acid or 
conjugate. The specificity of the antibodies is variable, but well circumscribed. The 
sensitivity is high (88, 89). 
2.5.3.3. Enzymatic methods use oxydation of -OHgroups present in the bile acid 
moiety. The most frequently used method specifically determines the presence of a 
free 3a-0Hgroup (found in 95"7o of all bile acids in the serum). The sensitivity is 
limited but sufficient (31). 
2.6. The interrupted enterohepatic circulation (EHC) of bile acids. 
Since 1965, several authors have reported on steatorrhea with decreased or absent 
recycling of bile acids after ileal resection. In 1967, Austad (54) reported two 
patients with this syndrome; one of them had chronic diarrhea following pelvic 
radiotherapy. After intravenous injection of I4C labeled taurocholic acid, almost 
none of the radioactivity was recovered on duodenal samplings, while 70-80% was 
recovered in controls. This indicated decreased recycling of bile acids. Heaton (55) 
repeate~ the test with either I4C labeled taurocholic acid or I4C labeled glycocholic 
acid, labeled in the steroid moiety. He observed the same lack of recovery. Another 
interesting finding was that the amount (very small) of residual radioactivity in duo-
denal samplings obtained at 24 hours was the same, regardless whether taurocholic 
acid or glycocholic acid had been injected. Only 10% of the bile acids were 
tauroconjugates. This indicates that in the colon glycine and taurine were completely 
split off and at subsequent reconjugation in the liver mainly glycine compounds 
were formed. 
The patients described by Austad et a!. (54) had the following features in common; 
whether caused by radiotherapy or by other factors, the syndrome of the interrup-
ted enterohepatic cycle consists of: 
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I) diarrhea; 
2) steatorrhea, often mild; 
3) malabsorption of bile acids; 
4) ileal disease in most cases. 
The major clincial feature is diarrhea caused by an increased overflow of bile acids 
into the colon. Dihydroxy bile acids are cathartics, i.e. they induce water and elec-
trolyte secretion in the colon and stimulate motility of the colon. Steatorrhea is a 
common, but not essential finding, depending on whether the faecal loss of bile 
acids results in bile acid depletion in the small intestine to the extend that ingested 
fat can no longer be emulsified. As the result of the decreased reabsorption in the 
ileum, the amount of bile acids returning to the liver is reduced. This causes in-
creased de novo sythesis of bile acids in the liver until a new steady state is reached, 
resulting in a sustained overflow of bile acids into the colon, thus maintaining diar-
rhea (Figure 2a, 2b pages 28, 29). The observed diarrhea has been termed "cholo-
genic diarrhea" and the syndrome "cholerheic enteropathy" (90). No investigations 
concerning the natural course of this syndrome have been done. A number of 
questions therefore remains, such as: will the liver go on synthesizing bile acids at a 
higher level and will the remaining small bowel eventually compensate for the loss of 
function? 
Clinical experience suggests that no adaptation takes place. The symptoms remain 
unchanged. It should be noted that these observations concern interruption of the 
EHC not only from radiotherapy but from any cause. 
2.7. Interrupted enterohepatic circulation (EHC) after radiotherapy. 
During radiotherapy for gynaecological malignancies, a varying length of the small 
intestine lies within the treatment area. A large proportion of this consists of 
terminal ileum. 
If radiation injures specific bile acid reabsorption sites in the terminal ileum, bile 
acid malabsorption with its concomitant diarrhea may contribute to the symptoms 
of radiation enteritis. 
Berk (61) suggested that one of the main mechanisms of radiation enteritis was 
"cholerheic enteropathy". He suggested the prevention of diarrhea with cholestyra-
mine. Several other authors have also suggested the importance of bile acids in 
relation to radiation damage to the intestine. 
Jackson (60) reported that, in experimental animals, interruption of the entero-
hepatic circulation by means of a bile fistula reduced the symptoms after irradiation 
and resulted in smaller loss of electrolytes and in a longer survival time. 
The interruption of the enterohepatic circulation was demonstrated by different 
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Fig. 2A: Partial interruption of the enterohepatic circulation leading to decreased bile acid reabsorption 
and increased faecal loss, which leads to moderate diarrhea. The amount of bile acids returning 
to the liver by portal venous system is decreased and as a result the synthesis by the liver 
increased. The bile acid concentration in the intestinal lumen is within normal ranges, thus 
preventing steatorrhea. 
methods: Austad (54) used duodenal intubation with an isotope dilution technique; 
Van Blankenstein (62) measured faecal excretion of I4C labeled taurocholic acid; 
Stryker (63) used the I4C-cholylglycine breath test. More recently (64) he determined 
the bile acid concentrations in peripheral venous blood (Radioimmuneassay). 
A decreased recovery of labeled bile acids in the bile, an accelerated faecal excretion 
of labeled bile acids, an increased excretion of I4CQ2 in the breath test and a de-
crease in postprandial concentrations of bile acids in the serum all indicated an 
impaired reabsorption of bile acids after irradiation. 
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Fig. 2B: More severe interruption of the enterohepatic circulation leading to decreased bile acid reab-
sorption. increased faecal loss and severe diarrhea. The amount of bile acids returning to the 
liver by venous portal system is reduced strongly. In spite of maximally increased synthesis, the 
bile acid concentration in the intestinal lumen drops below the critical micellar concentration 
and steatorrhea develops. 
2.8. Physiology of the rectum. 
The ampulla recti has a reservoir function. The wall of the rectum allows volume ex-
tension. As soon as the sigmoid is maximally filled, a both intrinsic and spinal reflex 
sets in motion a propulsive peristaltic wave. When the faeces reaches the rectum, the 
pressure inside increases and the wall is stretched. This is registered by stretch recep-
tors, which in turn decrease the tone of the internal anal sphincter while the external 
anal sphincter tone increases, thus closing the anal canal. The volume of the am-
pulla recti increases under the influence of the increased pressure, until the pressure 
becomes normal again. Then the internal sphincter regains its tone. If the pressure 
remains elevated, the patient will experience an urge to defaecate, accompanied by a 
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continuous relaxation of the internal anal sphincter. If the person responds to the 
urge to defaecate, he adopts the defaecation posture and the barriers to defaecation 
are removed by a straightening of the anorectal angle and relaxation of the sphincter 
(94). 
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CHAPTERUI 
STUDY DESIGN 
3.1. Background. 
Throughout the literature, the incidence of radiation damage of the intestine varies 
considerably. This is due to differences in definition and partly to differences in 
radiotherapeutic strategy. On the basis of our previous experience we have dis-
tinguished two types of radiation damage to the intestine: 
I) severe complications which include fistulas, stenoses, ileus and malabsorption 
with weight loss and rarely perforation; 
2) relatively mild complications like diarrhea and faecal incontinence without 
weight loss. 
We have concentrated on the incidence of these relatively mild complications during 
irradiation. They are termed acute effects or acute radiation reactions. When these 
relatively mild symptoms occur after completion of the irradiation, they are termed 
"late" effects. 
The pathophysiology of the postirradiation diarrhea is not clear. Although there are 
several indications that a disturbed reabsorption of bile acids plays a role, the rela-
tively low total daily faecal weight is not in agreement with this assumption. When 
the study began, there was no literature available on a possible direct effect of radia-
tion on the rectosigmoid function. 
3.2. Working hypothesis. 
Our working hypothesis is based on the results of a clinical study (84). In this study 
the combination of diarrhea, faecal incontinence, impaired bile acid reabsorption 
and a relatively low daily faecal weight was found. 
Whereas in the literature, fistulas and stenoses form the main topic of publications 
on radiation bowel damage, we thought it important to concentrate on a less severe 
damage. Therefore, we have chosen a change in stool habits, e.g., diarrhea, as the 
phenomenon to be studied. 
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Our first assumption was that irradiation of the pelvic region leads to damage of the 
ileal mucosa. As a result, the enterohepatic circulation of bile acids would be inter-
rupted and this would manifest itself as impaired reabsorption of bile acids. With 
appropriate tests this impaired reabsorption would result in two phenomena: 
1) a lower than normal bile acid concentration in the serum at ± 2 hours after the 
emptying of the gall bladder, i.e., after a test meal (postprandially); 
2) a shortening of the biological half-life of an orally administered dose of radio-
actively labeled bile acid. 
Our second assumption was that the faecal incontinence was not only the direct 
result of the irradiation but also of a pre-existing weak anal sphincter mechanism 
(81), especially in multiparous women. The fact that this latent incontinence had not 
become manifest, should then be attributed to the firm stools that result from the 
average Dutch diet. However, when the stool consistency would change to watery, 
the incontinence would become manifest. From these two assumptions, the fol-
lowing hypothesis was adopted for this study: The cause of the clinical symptoms 
after radiotherapy to the pelvic region is a combination of impaired reabsorption of 
bile acids and a pre-existent, but latent, impaired faecal continence. 
It seemed logical to test this hypothesis by measuring the bile acid losses as well as 
the anal sphincter mechanism in a population of patients irradiated for pelvic malig-
nancy. 
3.3. Patient selection. 
Eligibility and entry criteria. 
Patients were admitted to or excluded from the study on the basis of the following 
criteria. 
Eligibility: 
Patients referred to the Rotterdamsch Radio-Therapeutisch lnstituut (RRT!) for 
radiotherapy of a carcinoma of the cervix or of the uterine corpus. 
This could be for either exclusive radiotherapy (carcinoma of the uterine cervix) or 
postoperative radiotherapy (either a carcinoma of the endometrium or the uterine 
cervix). The treatment consisted of a course of megavoltage external irradiation 
with or without intracavitary treatment. 
Exclusions: 
1) patients unable to fulfil protocol requirements as given below; this could be due 
either to health problems or sociogeographical problems; 
2) patients with a colostomy; 
3) patients with acute or chronic overt gastrointestinal disorders. 
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Patients thus entering the study were registered and the following pretreatment rou-
tine had to be completed: 
I) medical history and physical examination; 
2) routine hematology and biochemistry; 
3) serum bile acids determined in the fasting patient and at 2 hours after a meal; 
4) diet history taken by a dietitian; 
5) a questionnaire concerning bowel motions ftlled out by the patient; 
6) a faecal continence test according to Read (81) performed*; 
7) all stools collected over a 4 day period; 
8) faecal excretion of a tracer dose of isotope labeled bile acid determined** (62). 
During irradiation, the patients kept daily records of their bowel movements. ·They 
visited the dietitian at least once a week and were given dietary advice mainly when 
they complained about diarrhea, both in the acute and in the follow-up period. 
The following determinations were repeated in the middle of the course of radio-
therapy and at the end: 
I) serum bile acids, fasting and postprandial; 
2) all stools collected over a 4 day period; 
3) faecal excretion of labeled bile acids. 
Follow-up: The first follow-up visit was at 6 weeks after the end of the irradiation. 
It consisted of a visit to the dietitian and radiation oncologist. The patient was asked 
whether she had symptoms and a physical examination was performed. The above-
mentioned determinations were repeated at 6 weeks and 6 months after the end of 
the treatment. 
During follow-up, patients regularly visited the out-patient department. During the 
first year, this was bimonthly, in the second year every 3 months and in the third 
year every four months. During the fourth year, this took place every six months 
an.d from then on at least once a year. At these visits, the patient was seen by there-
ferring gynaecologist or by the radiation oncologist on an alternating basis. 
A total of 196 patients has been studied; 109 with carcinoma of the uterine cervix 
and 87 with a carcinoma of the endometrium. The mode of treatment is illustrated 
in Table I. 
"' introduced in 1981. 
""" only in a selected group of patients (Par. 3.5.2.) 
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~ TABLE I. The number of patients included in the study in relation to diagnosis and mode of treatment. 
exclusive 
/'""""'"'"" 
carcinoma of the 
109 
/"'"'"' re"'' 
\'"'"'=''"' Total number 196 radiotherapy 
of patients 
\='"""'' "' "" ''"'""'"""' endometrium radtotherapy ~exclusive 
radiotherapy 
LDR = intracavitary irradiation at low dose rate 
HDR = intracavitary irradiation at high dose rate 
external irradiation 
67 ------------ external irradiation + LDR ~ external irradiation + HDR 
------------ external irradiation 
42 external irradiation + LDR ~ external irradiation + HDR 
------------ external irradiation 
85 ~external irradiation + LOR 
external irradiation + HDR 
2 external irradiation + LDR 
2 
20 
45 
3 
3 
36 
5 
79 
2 
3.4. Methods of treatment. 
3.4.1. History of the treatment protocols at the Rotterdamsch Radio-Therapeutisch 
Instituut. 
3.4.1.1. External irradiation. 
Until 1965, external irradiation was generated by 200-300 KV ortbovolt machines. 
Then, megavolt equipment became available. At first, 60 Co (1.25 MeV) was used 
and later linear accelerators with increasing energies of 4 up to 32 MeV were em-
ployed. 
The advantages of this megavolt irradiation were: 
I) greater penetration resulting in a higher dose at the required depth; 
2) lower surface dose, thus sparing the skin; 
3) shorter treatment time; 
4) less difference in absorbed dose in soft tissues and bone; 
5) less scatter, which means sharper edges of the treatment field. 
With orthovolt machines, the target volume included the parametria and the main 
dose-limiting factor was the skin. With the introduction of megavolt machines, the 
total dose could be increased from 30 - 50 Gy. 
In the early years of megavolt therapy, the target volume (as used in conventional 
orthovolt therapy) was not increased. Later, it was enlarged to include the regional 
iliac lymph nodes up to the level of the aortic bifurcation. 
Field sizes were determined by anatomical reference points. Three categories of field 
size can be distinguished: 
I) standard gynaecological pelvic portals (sgp), 
2) sgp and para-aortic portals (sgp + pao ). 
3) whole pelvic peritoneal cavity (wpp) + pao, 
Fig. 3A; 
Fig. 3B; 
Fig. 3C. 
The standard gynaecological pelvic portals (Fig. 3A) encompass the area of the 
primary uterine tumour and the regional lymph nodes, including those at the aortic 
bifurcation. In the case of proven lymph node involvement within this area, the 
para-aortic nodes were included (sgp + pao, Fig. 3B). In this case the lower border 
of Thl2 is taken as the upper limit of the field. Growth of the primary tumour pen-
etrating the uterine wall and/or ovarian or pelvic peritioneal metastases were condit-
ions for extending the target volume to the whole pelvic peritioneal lining (wpp + 
pao; Fig. 3C). 
A tumour in the lower third of the vagina and/ or metastases in the inguinal lymph 
nodes were indications for including the whole vagina and/or the inguinal areas in 
the target volume. 
35 
The treatment technique is dependent on the central abdominal diameter of the 
patient. If this does not exceed 20 em, only anterior-posterior fields are used. When 
it measures more than 20 em, a combination of anterior-posterior and lateral fields 
is used in order to spare the skin. The lateral portals (Fig. 30) encompass the area of 
the standard pelvic portals. During 1980, the use of lateral portals was discontinued, 
for technical reasons. 
Fig. 3A: Standard gynaecological pelvic 
portals (s.g.p.). 
Fig. 3B: Standard gynaecological pelvic plus 
para-aortic portals (s.g.p. + p.a.o.). 
3.4.1.2. Brachytherapy is therapy from close by. This can be performed as either in-
terstitial therapy, which means inserting radioactive needles or wires into the tissues 
of the target volume, or as intracavitary therapy, which means application of radio-
active sources to an existing natural cavity, e.g., the vagina or the uterine cavity. 
From the beginning of this century, intracavitary treatment was performed by using 
radioactive sources in a preloaded applicator. The disadvantage of this system was 
the high radiation exposure for medical personneL To keep this exposure as low as 
possible, the time available for applications or dosimetry had to be short. For the 
patient, the long treatment times (sometimes up to 5 days) were very troublesome. 
With the introduction of "after-loading" techniques, the exposure of medical 
personnel was reduced. In this technique the applicator was inserted without radio-
active sources. Dosimetry could then be performed at leisure, while the sources were 
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Fig. 3C: Whole pelvic peritoneal lining plus 
para-aortic portals (w.p.p. + p.a.o.). 
Fig. 3D: Lateral pelvic portals. 
introduced afterwards. The discomfort to the patient and the radiation exposure to 
the nursing staff, however, remained the same. 
In 1964, Henschke (33) developed the first remote-control after-loading device: 
from outside the treatment room, the radiation sources could be removed from the 
patient before the personnel entered the room; this decreased exposure of the nurs-
ing staff to minimal levels and provided better conditions for delivering nursing 
care to the patient. 
The remaining problem thus was the long treatment time and, inherent to this, the 
uncertainties in the dose distribution for the healthy tissues at risk (due to possible 
change in position of the applicator). 
There are radiobiological data (96) to suggest that a low dose rate, which implies the 
long treatment time, is of advantage for the treatment of some tumours and for 
sparing normal tissues, especially when the cells have a short cycle time. Some 
clinicians attempted a compromise by using intermediate dose rates that permitted 
the total treatment time to be reduced to about 24 hours. 
In 1967, O'Connel (34) introduced the first high dose rate remote-control after-
loading machine for intracavitary treatment, the Cathetron. The treatment time per 
session could now be reduced to 5 - 30 minutes, depending on the activity of the 
sources. Even treatment on an out-patient basis became possible. 
For the intracavitary treatment of carcinoma of the uterine cervix, the modified 
Stockholm system (92) was used at our Institute until 1980. This system involved 3 
applications separated by about 2 weeks. During the first application a vaginal box 
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with a diameter according to the size of the cervix is placed against the cervix at the 
top of the vagina. During the second application, an intrauterine tube is inserted 
into the uterine cavity. The length of this tube is adjusted to that of the intrauterine 
cavity. The third application is the same as the first one. The intrauterine applicator 
was after-loadable; most vaginal applicators were not. 
For postoperative treatment of carcinoma of the uterine cervix, one or two vaginal 
applications with a vaginal box were performed. 
For postoperative treatment of carcinoma of the endometrium, a vaginal cylindrical 
applicator with one linear central source and two semi circular top sources was used. 
The length and diameter of these cylinders were adjusted to the size of the postoper-
ative vagina. These applicators were after-loadable. 
In 1976, the treatment with the Cathetron machine was started at this Institute, at 
first for only the postoperative treatment of carcinoma of the endometrium. Since 
1978, it has also been used for postoperative treatment in carcinoma of the cervix. 
In 1980, it was further extended to curative treatment of carcinoma of the cervix, 
exclusively by means of radiotherapy. 
Along with its introduction in the curative treatment of carcinoma of the cervix, our 
treatment policy was changed. The former treatment policy was as follows. The tar-
get area of the intracavitary treatment was the region of the primary tumour and the 
main goal of the external irradiation was the treatment of the regional lymph nodes. 
During the external irradiation or at least part of it, the effective area of the intraca-
vitary treatment was shielded off (treatment strategy A). If this policy had been con-
tinued with the Cathetron, at least 4-5 applications would have been necessary. This 
would have meant a great burden on the patient and the department. Therefore, the 
strategy was changed as follows. The external irradiation covered the target area of 
the intracavitary irradiation as well as the regional lymph nodes and, after comple-
tion of the external beam therapy, a booster irradiation with intracavitary treatment 
was given to the area of the primary tumour (treatment strategy B). This also gave 
us the opportunity to eliminate uncertainties in dose that always exist at the edge of 
a shielded area. 
3.4.2. Total dose and fractionation. 
3.4.2.1. External irradiation. 
The total dose and the fractionation schedule were chosen according to the field 
size. When standard gynaecological pelvic portals were used, daily fractions of 2.0 
Gy were applied. When the para-aortic nodes were included, the fraction size was 
decreased to 1.8 Gy and, if the large pelvic portals were applied, it was further 
reduced to 1.5 Gy. 
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Two treatment strategies were used consecutively during this study. 
A) In the treatment of carcinoma of the uterine cervix, in 800Jo of the fractions of 
external irradiation, central shielding of the effective area of the intracavitary 
treatment was done. In postoperative treatment of a carcinoma of the endo-
metrium, 300Jo of this area was shielded. 
B) In this treatment policy, no central shielding was used and, after the external ir-
radiation, an intracavitary booster treatment was administered to the area of the 
primary tumour. 
Table II: The fractionation schedules used throughout this study. 
Treatment Treatment Total dose (Gy) Number of Dose per 
strategy area fractions** fraction (Gy) 
A sgp 50.0 25 2.0 
A sgp + pao 52.2* 29 1.8 
A wpp + pao 54.0* 36 1.5 
B sgp 46.0 23 2.0 
B sgp + pao 48.6 47 1.8 
B wpp + pao 49.5 33 1.5 
"'The para-aortic region is shielded after 40-45 Gy. 
*"' Daily fractionation: 5 fractions a week. 
The total dose and fractionation before the introduction of the Cathetron (strategy 
A) is shown in Table II. 
When the fraction dose was changed, the number of fractions and the total dose had 
to be adjusted. In order to achieve the same biological effect, this was done accord-
ing to the nomogram of Shuttleworth and Fowler (35). When we changed the strat-
egy, the total irradiation dose was decreased to 46 Gy for standard gynaecological 
pelvic portals and in the same degree for the other portals (strategy B; Table II). 
3.4.2.2. Intracavitary irradiation. 
With strategy A, the following treatment schedules were applied: 
I) Carcinoma of the uterine cervix exclusively treated by irradiation. The 
course of external beam therapy was interrupted in order to apply intracavi-
tary treatment after 1, 3 and 5 weeks. Thirty Gy in two fractions (first and third 
interruptions) were delivered at a dose rate of 0.5 G:,: per hour with a vaginal 
box and 30 Gy in one fraction at a dose rate of 0.6 Gy per hour with the uter-
ine applicator. These doses were specified at point A (2 em cranially of the for-
nix lateralis and 2 em laterally of the uterine axis; Figure 4 ). 
39 
Vaginal 
ovoids 
' I 
I I A' 
' ~----- -- --~-
1 2 em 
Vaginal 
ovoids 
_!_ 
Fig. 4: Schematic representation showing .. point A" (left) and "point A'" (right). 
"Point A" 2 em cranially of the forni:" lateralis and 2 em laterally of the uterine axis (after 
Todd and Meredith: ref. 32) and "point A ... , reference point for postoperative intracavitary ir-
radiation, 2 em cranially of the vaginal vault and 2 em laterally of a line between the ovoids. 
II) Carcinoma of the uterine cervix treated by surgery and subsequent irradiation. 
The course of external therapy was interrupted in the first or second week to 
deliver by means of a vaginal box a dose of 15 or 30 Gy in one or two fractions 
at a dose rate of 0.5 Gy per hour. These doses were specified at point A' (2 em 
cranially and 2 em laterally of the vaginal vault; figure 4). 
III) Carcinoma of the endometrium treated by postoperative irradiation. The 
course of external beam therapy was interrupted during tbe first or second 
week for two consecutive days to administer two fractions of 8.0 Gy in about 
20 minutes at a deptb of 0.5 em from the vaginal epithelial lining by means of 
a cylindrical vaginal applicator. 
In strategy B, the following treatment schedules were applied. 
I) Carcinoma of the uterine cervix treated exclusively by irradiation. The 
course of external therapy was not interrupted, but intracavitary treatment 
started at two weeks after completion of this course. Then two combined 
(intravaginal and intrauterine) applications, separated by one week were 
given. With each application, a dose of 8.5 Gy was delivered to point A in 
25 minutes. 
II) Carcinoma of the uterine cervix treated by surgery and subsequent irradiation. 
The course of external beam therapy was not interrupted, but intracavitary 
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Fig. 5: Lateral representation of a radiograph taken from a patient treated postoperatively with intra-
cavitary irradiation for a carcinoma of the uterine cervi.'l:. 
Note the little chain which marks the floor of the bladder. The distance between the central axis 
through the vaginal ovoids and the chain in the bladder: x is used for dose specification. 
Note the proximity of the small bowel and the rectum to the sources. 
treatment was started at two weeks after the completion of the course. 
Then, two applications, separated by one week, each delivering 6.5 Gy in 35 
minutes at point A', were given. More recently, instead of two applications, 
only one ·has been given, but the dose has been increased to 9.25 Gy in about 
25 minutes. At the same time, the depth at which this dose was delivered was 
then individualized for each patient. This was done by determining the dis-
tance between the ovoids source position and the lining of the bladder mucosa 
on a radiograph as indicated by a small chain inserted into the bladder (Fig. 5). 
Ill) Carcinoma of the endometrium irradiated exclusively as an adjuvant to 
surgery. 
The course of external therapy was not interrupted, but intracavitary (vaginal) 
treatment was started at two weeks after the completion of the course. A single 
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application delivering 9.0 Gy at a depth of 0.5 em in about 25 minutes was 
given. 
A schematic representation of the schedules applied is shown in Figure 6. 
FRACTIONATION SCHEDULES USED THROUGHOUT THIS STUDY. 
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Fig. 6: Fractionation schedules of external and intracavitary irradiation according to diagnosis and 
treatment strategy. For treatment strategies A and B, see par. 3.4.2.2. 
3.4.3. Dosimetry. 
3.4.3.1. External irradiation. 
The total delivered dose was specified in the midplane. We assumed that an equal 
dose was delivered at the dose reference points, respectively, points A en A' (Figure 
4, page 40). 
3.4.3.2. Intracavitary irradiation. 
As mentioned above, the doses delivered in intracavitary irradiation for carcinoma 
of the uterine cervix were specified at points A and A' (for postoperative irradia-
tion). For postoperative irradiation in carcinoma of the endometrium, the delivered 
dose was specified at a depth of 5 mm beneath the epithelial lining of the vaginal 
wall. These doses were converted to the dose at point A'. For the calculation of the 
absorbed dose in the small intestine the patient was given 200 ml of barium orally at 
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one hour before the application. After insertion of the applicator, anterior-posterior, 
lateral and stereo radiographs were taken (examples are shown on page 44 and 45). 
With stereo X-ray photogrammetry (66, 83), we were able to calculate the absorbed 
dose at several points of the intestine. It should be pointed out that these photos 
were not diagnostic radiographs; therefore, there was not always an optimal filling 
of the bowel. 
For the calculation of the total absorbed dose (external plus intracavitary) in the 
small intestine, the highest detected dose was taken into account. The combination 
of external and intracavitary irradiation was expressed according to the TDFformu-
la and for a subgroup, also according to the L-Qformula. For the TDF and 
L-Qformulas used, see Appendix !. 
3.5. Tests for intestinal function. 
A table giving all the tests and the times at which they are performed is shown in 
Appendix II. 
3.5.1. Serum bile acids were measured according to the enzymatic 3 "hydroxyster-
oid dehydrogenase method (sterognost- 3 "RRA) (31). 
This test set contains a lyophilized preparation of 3 "HSD, NAD, buffer salts and 
stabilizers. In a bile acid containing serum sample, the reaction as shown below will 
occur. 
3 " hydroxy bile acid 
NAD+ 
3 " keto bile acid 
NADH + H+ 
The amount of NADH generated from the oxidation of the bile acid in the serum is 
then determined spectrophotometrically with an LKB Reaction Rate Analyzer (31). 
This enzymatic method determines the total quantity of bile acids, but does not dis-
criminate between different bile acids. The bile acids which are sulfated or glucuro-
nidated at the 3 " position cannot be determined. The reproducibility is satisfactory 
within a run as well as for day to day runs. The coefficient of the variation is about 
10% for values in the range of 4 JLIIlOI/1 and decreases to around 6"7o for values in 
the order of 10 l'mol/1 (31). Total serum bile acids were determined in the fasting 
state and at two hours after a standard meal which consisted of orange juice, scram-
bled eggs, toast and coffee. In a subgroup of patients, serum samples were taken 
when fasting and every 30 minutes up to two hours after ingestion of the standard 
meal. This was done in order to get a better impression of the postprandial changes 
in serum levels and to test the validity of the two hour postprandial sampling in the 
entire group of patients. 
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Foto Ap:Anterior-Posterior (AP) radiograph and schematic representation for dosimetric purposes. Note 
the proximity of the rectum and small intestinal mass to the ovoids and intra-uterine tube. The 
small chain in the bladder indicates the floor of the bladder. which is also closeby. 
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Lateral: Lateral radiograph and schematic representation for dosimetric purposes. Note the proximity of 
the rectum and small intestinal mass to the ovoids and intra-uterine tube. The small chain in the 
bladder indicates the floor of the bladder, which is also close by. 
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3.5.2. Faecal excretion of bile acids. 
The patients were asked their consent before this test was performed. The biological 
half-life of an orally administered tracer dose of radioactive labeled cholic acid was 
determined as follows. At time 0, a dose of 200 KBq (5 I'Ci) I4C labeled taurocholic 
acid or 370 KBq (10 JLCi) 75Se labeled homotaurocholic acid was administered. 
During the following 5 days, all stools were collected in 24-hour portions. To judge the 
reliability of the collection, 25 radioopaque markers were also administered at time 
0. At least 20 markers had to be recovered in the stools to consider a test reliable. 
For I4C, the determination of the excreted radioactivity was done according to the 
method described by Van Blankenstein eta! (62) and, for 75Se, according to Delhez 
et a! (65). The biological half-life (T /2) and the curve of disappearance could be 
calculated from the daily excretion counts. 
3.5.3. Faecal weight. 
For 4 consecutive days all stools were collected in 24-hour portions. The specimen 
collection containers were then weighed and, after subtraction of the empty weight, 
a mean daily faecal weight was calculated over this 4-day period. 
3.5.4. Transit time. 
The 25 markers were administered at time 0. Then, during 4 days, all stools were 
collected in 24-hour portions. The collecting containers were X-rayed and the num-
ber of markers in each collector counted. 
The mean intestinal transit time in days was then calculated according to the follow-
ing formula: 
MTT (n1 x I) + (n2 x 2) + (n3 x 3) + (n4 x 4) 
n 
In this formula n1, n2, n3, n4 and n stand for the number of markers on each day and 
the total number of markers counted, as proposed by Cummings (47). 
3.5.5. Continence test. 
Patients were tested with a rectal saline infusion test as described by Read (81); 
1500 ml of normal saline at body temperature was· infused into the rectum at a 
constant speed of 60 ml per minute. The patients sat on a chair with a central ope-
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ning and a collector underneath. They were asked to try to retain all of the infused 
saline. The two factors in this test were the volume infused at the time that the first 
leakage occured and the total volume leaked by the end of the test. 
3.5.6. Diet history. 
Prior to the irradiation all patients paid a visit to the dietitian. For one week, they 
kept records of everything that they ate and drank. These data were analysed and 
scored on composition (fat, carbohydrates, proteins, etc.). The scoring system is 
shown in Appendix Ill. 
3.5. 7. Stool habits. 
3.5.7.1. Acute reactions. 
The patients kept daily records of their stool habits during the irradiation on a form 
which was distributed before the start of the irradiation. They were asked to not on 
this form all additional complaints and medication used. Theis list was checked by 
the dietitian at least once a week. 
3.5. 7.2. "Late" effects. 
A history of stool frequency, consistency of the stools and the occurrence of ab-
dominal cramps was recorded at each follow-up visit. Changes in stool habits were 
arbitrarily scored. 
Stool frequency: 
0 = no change 
1 = variably increased, 0-2 x 
2 = 2-3 x increased 
3 = 4-5 x increased 
Stool consistency: 
0 = no change 
1 = variably changed 
2 = only watery stools 
Abdominal cramps: 
0 = none 
I = abdominal cramps 
The scores for frequency and consistency were added to express the change in stool 
habits (class 0-6). 
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3.5.8. Continence. 
During follow-up, the patients were asked to fill out a questionnaire (Appendix IV) 
concerning their faecal continence. The anwers were arbitrarily scored as 0-4. 
0 no change 
I faecal urge 
2 serious imperative urge 
3 incidental incontinence 
4 continuous incontinence. 
3.6. Statistics. 
For statistical analysis of the data, nonpararnetrical methods were used. The nature 
of the analysis was in the first place descriptive. Median values and interquartile 
ranges of scores and differences were calculated. To estimate the change of values in 
time, Wilcoxon's matched pairs signed rank test was used. 
Differences between subgroups were analysed with Wilcoxon's rank sum test, a chi 
square test or Fischer's exact test. 
Spearman's rank correlation was used to estimate the correlation between ordinal 
variables and scores of differences. 
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CHAPTER IV 
RESULTS OF INTESTINAL FUNCTION STUDIES. 
In our patient population it was not always possible to perform all tests at the sched-
uled intervals. This resulted in exclusion of varying numbers of patients for each 
test. The inclusion criteria employed are given with each set of results. 
4.1. Serum bile acids. 
For the serum bile acid study patients were regarded as evaluable if at least three test 
results out of the possible five were obtained. Between January 1980 and January 
1982, 196 patients proved to be evaluable for a longitudinal study of bile acids. The 
median values (and interquartile ranges) of the fasting level and the two-hour post-
prandial serum level of bile acids are shown in Fig. 7. The difference between the 
two-hour postprandial and fasting levels, the postprandial increase is shown in 
Figure 7 (and Appendix V). 
The median fasting level decreased during radiotherapy and gradually returned to 
pretreatment values. The median two-hour postprandial level decreased consider-
ably during therapy but returned to its pretreatment level after 6 weeks. As a conse-
quence, the median postprandial increase became less during therapy, with a ten-
dency to recover at 6 weeks. At 6 months, however, it was again somewhat below 
pretreatment levels. After exclusion of the 31 patients who had undergone gastric 
surgery or cholecystectomy the results for the remaining 165 did not differ from that 
of the original 196. Patients treated for carcinoma of the endometrium had higher 
fasting and two-hour postprandial levels than did those treated for carcinoma of the 
uterine cervix before as well as after radiotherapy (Figure 8). 
Any type of previous abdominal surgery followed by radiotherapy was also associ-
ated with higher fasting and postprandial levels (Figure 9). 
The serum bile acid levels determined at half-hour intervals for up to two hours 
postprandially are shown in Figure 10. 
It can be seen that, during radiotherapy, the median values were below the pretreat-
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Fig. 7: Serial serum bile acid levels during and after pelvic radiotherapy. Fasting (o') and 2-hour post-
prandial values (120') at different times. On the right, the postprandial serum bile acid increase 
is plotted. There is a temporary fall in serum bile acid concentrations. 
(B = before RT; H = midway RT; E = End of RT; P = 6 weeks after RT; C = 6 months 
after RT). 
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Fig. 8: Serial serum bile acid levels of patients with carcinoma of the uterine cervix (a) and those with 
carcinoma of the uterine corpus (x). (Median values; abbreviations see legend fig. 7). 
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SERUM BILE ACIDS ACCORDING TO ABDOMINAL SURGERY. 
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Fig. 9: Serial serum bile acid levels in patients who were subjected to any abdominal surgery (o) and 
those who had not undergone surgery (x). (Median values: abbreviations see legend fig. 7). 
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Fig. 10: Results of endogenous tolerance tests for serum bile acids (samples taken half hourly from 
fasting up to two hours postprandially) at different times during and after pelvic radiotherapy. 
During pelvic irradiation, lower serum bile acid concentrations are found after a test meal (a 
and b). (Abbreviations see legend fig. 7). 
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ment level at 30, 60 and 90 minutes. At six weeks after treatment, bile acid concen-
trations returned to pretreatment levels. At six months after treatment, the number 
of patients re-examined was too small to allow a comparison with pretreatment 
values. 
To test the validity of the two-hour postprandial sampling in the total group of 
patients, the time of the peak values was noted. Before and at six weeks after 
irradiation, the median peak value was recorded at 90 minutes after the test meal; 
but, midway through the radiotherapy, it was recorded as late as two hours post-
prandially, although there was a considerable variation. The height of the peak, 
however, showed a significant decrease during therapy, followed by an increase to 
pretreatment levels at six weeks after treatment (Figure II). 
4.2. Faecal bile acid excretion. 
The faecal loss of a radio labeled taurocholic acid tracer dose was determined. From 
these losses, the biological half-life (T /2) was derived. Faecal bile acid excretion fig-
ures were available for 33 patients, although not in every phase of the study. In 7 
patients, only one observation was available. These cases could not be used for stat-
istical analysis, as only paired results for each patient were useful for this purpose. 
The reasons for missing or non evaluable data were sampling errors, recovery of in-
sufficient numbers of markers in the stools, refusal to cooperate, etc. 
The median values for the biological half-life of a labeled bile acid dose (T /2) are 
shown in Figure 12. 
This plot shows that the T 12 was shortened at the end of treatment, indicating a de-
creased reabsorption of cholic acid. After an initial improvement at six weeks, T 12 
was again below the pretreatment level at six months after radiotherapy. 
As none of these patients had any bowel complaints on entry into the study, the test 
results at the start of radiotherapy (B) represent the "normal values" for his group 
of patients. A rather broad variation is evident. 
4.3. Mean intestinal transit time. 
The patients had to have at least two test results to be included in the analysis. 
Transit times were calculated from recovered stool markers in 92 patients at differ-
ent times during and after pelvic radiotherapy. 
The mean distribution of marker recovery showed that the major portion of the 
markers was excreted during the first two days (Fig. !3). Frpm the marker recovery, 
the mean transit was calculated (Fig. 14). At six weeks after treatment the mean 
transit time was slightly increased as compared with that at the beginning (B) and 
the end (E) of radiotherapy. No difference from B was observed at six months. 
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Fig. 11: The peak serum bile acid concentrations after a test meal at different times during and after 
pelvic radiotherapy. A temporary decrease is observed at H. (Median values and interquartile 
ranges: abbreviations see legend fig. 7). 
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Fig. 12: Biological half-life (T /2) of an isotope labeled (14C or 75Se) cholic acid tracer dose during and 
after pelvic radiotherapy (median values and interquartile ranges; abbreviations see legend 
fig. 7). 
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Fig. 13: Marker profiles during four days (24 hours periods) after ingestion of 25 nonresorbable radi-
oopaque markers during and after pelvic radiotherapy. 
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Fig. 14: Transit time at different times during and after pelvic radiotherapy (median values and inter-
quartile ranges: abbreviations see legend fig. 7). 
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4.4. Total daily faecal weight. 
The patients had to have at least two test results to be included in the analysis. 
The mean faecal weight was determined in 92 patients. A number of results had to 
be discarded because of insufficient marker recovery: 8 patients at the start of treat-
ment (B), 27 at the end (E), 17 at 6 weeks after treatment (P) and 3 patients six 
months after treatment (C). 
The median values for faecal weight at different times during and after pelvic radio-
therapy are shown in Fig. 15. 
It can be seen that, at the end of radiotherapy, the mean faecal weight had increased 
considerably, but returned to pretreatment levels at six weeks after radiotherapy. 
4.5. Faecal continence test. 
One-hundred and nine patients were tested for continence. The median value for the 
instilled volume at which the first leakage occurred was 200 ml (interquartile range, 
100-300 ml). 
The median value for the total leaked volume was 1100 ml (interquartile range 500-
1400 ml). Twelve patients experienced no leakage at all. Twenty-two patients had 
leakage from the start of the test. There was a strong relation between the time of 
the first leakage and the total leaked volume; patients who leaked early leaked more. 
No relation was found between the age of the patient, parity and the test results. 
4.6. Diet history. 
The diet histories of 155 patients were available for analysis. The results are shown 
in Appendix VI. For most of the diet components, there was not much difference 
between individual patients, e.g. as far as proteins, fat or carbohydrates were con-
cerned. SOOJo of the patients fell in the "normal" intake range for proteins and carbo-
hydrates. A similar percentage proved to have somewhat elevated intake of fat. 
4.7. Clinical symptoms. 
4. 7.1. Acute reactions. 
During the acute phase of the radiation reactions, the most common symptom was 
diarrhea. At first, softening of the stool was noted; this was later combined with 
increased frequency. This increased frequency was especially noticeable in the morn-
ing hours or following food intake. In severe cases, it was combined with abdomi-
nal cramps and/ or production of mucus and sometimes blood. During this period, 
patients might complain of a faecal urge or even faecal incontinence. 
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Fig. 15: Mean total daily faecal weight at different times during and after pelvic radiotherapy (median 
values and interquartile ranges; abbreviations see legend fig. 7). During irradiation faecal 
weight temporarily increased. 
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Fig. 16: Mean daily stool frequency, calculated over a one-week period during pelvic radiotherapy. 
Note increasing frequency up to the fourth week. 
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The mean stool frequency during the first week of radiation was once a day. As 
shown in Fig. 16, the mean daily stool frequency calculated over one week increased 
during the first 4 weeks and then reached a plateau. In approximately 25"7o of the 
patients, the stool frequency did not change at all, it remained within the pretreat-
ment range. 
The so-called "diarrhea factor" indicates the ratio of watery stools to the total num-
ber of stools. This factor was used to express the change in stool consistency. Stools 
became more fluid during the first 3-4 weeks, after which a plateau was reached 
(Fig. 17). 
4. 7.2. "Late" effects. 
In most patients, the acute side-effects subsided within 2-3 weeks after the end of 
radiotherapy. The first follow-up visit to the out-patient department was scheduled 
6 weeks after the completion of radiotherapy (P). The mean follow-up time of our 
patient population was 17 months, range 6 to 31. Eleven patients were lost to 
follow-up. 
Of 185 patients, 59 experienced altered bowel motions during follow-up. 32/59 
patients complaining of diarrhea during follow-up had no symptom-free 
period at all between irradiation and their diarrhea. Another 15 patients got diar-
rhea within the first 6 months (C), while in another 8 the diarrhea became manifest 
after the end of the first year. 
The prevalence of "late" effects is shown in Fig. 18. This plot shows that, from the 
fifth month of follow-up onwards, the prevalence remained constant. In about 30"7o 
of the patients, the diarrhea eventually disappeared. In this subgroup the median 
duration of diarrhea was 6 to 7 months. 
The severity of the late effects was arbitrarily classified by adding the scores for each 
factor (stool frequency, stool consistency and abdominal cramps; scores ranging 
from 0-6; Par. 3.5.7.2, 3.5.8.), with the following results: 
18 patients were in class 1; 
17 patients class 2; 
15 patients 
7 patients 
2 patients 
4. 7.3. Continence. 
class 3; 
class 4; 
not classifiable. 
96/109 patients who had undergone a pretreatment continence test filled out a 
questionnaire. The results of this questionnaire sho)Ved no relation between the re-
sults of the continence test and the fact whether patients experienced faecal inconti-
nence during follow-up or not (Appendix VII). 
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Fig. 17: "Diarrhea factor" (number of watery stools/total number of stools calculated over a one-week 
period) for the entire group of patients. Note an increase during the first four weeks. 
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Fig. 18: Prevalence of "late" effects (number of patients with "late" effects, in relation to the total 
number of patients with the same duration of follow-up. 
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4.8. Patient risk factors. 
The incidence of several patient factors is shown in table III. 
Table III. 
present absent 
Abdominal surgery n = 137 n= 59 
Diabetes mellitus n= 18 n = 178 
Cardiovascular disease n= 38 n= !58 
This table indicates the number of patients in which the risk factors for bowel dam-
age mentioned in the literature are present or absent. The large number of patients 
with ''previous abdominal surgery" is caused mainly by the patients who were oper-
ated because of carcinoma of the endometrium. 
Table IV shows the mean values and the standard deviation for the age and body 
build related factors: 
Table IV. 
Age 
Height 
Weight 
AP diameter 
4.9. Radiotherapy factors. 
60 ± 11.9 years old 
162 ± 6.3 em 
69 ± J1.8 kg 
22.4 ± 6.2 em 
The mean values for the radiotherapy factors which were assumed to be risk factors 
for bowel damage, are shown in the following table M-
Table V. Mean values and ranges of radiotherapy factors 
Total dose 
Total treatment time 
Dose per fraction 
Time~ Dose-fractionation 
at point A 
at intestine 
treatment volume 
standard gynaecological 
pelvic portal (sgp) 
sgp + paraaortal 
4S.5 Gy 
49.5 days 
1.95 Gy 
91.9 
86.0 
5.770 em' 
7.760 em' 
range 
range 
range 
range 
range 
range 
range 
45.0 
- 56.0 
34 - 117 
1.5 2.0 
18 - 178 
23 - !55 
3.200 - 9.500 
4.800 - 12.900 
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4.10. Relation between the different test results. 
Prior to tbe irradiation, the expected relation was found between the stool frequen-
cy (once a day or less as compared witb more than once a day) and the transit time. 
In the group of patients witb a stool frequency equal to or less than once a day, the 
median value of the transit time was longer (see table VI). 
Table VI. The relation between the stool frequency(> 1 or< 1) and the intestinal transit time at diffe-
rent times during after irradiation 
Mean Transit time (days) 
Stool frequency 
< 
> 
Before RT 
2.0* 
1.6* 
(median values: "' = significant difference p < 0.05). 
End RT 
1.9 
1.8 
6 weeks after RT 
2.2 
2.0 
However, an overlap of the two groups was observed. Before as well as after ir-
radiation, the expected relation between the transit time and the faecal weight was 
found: a longer transit was associated with a lower faecal weight. These correlations 
were highly significant (p < 0.001). 
The relation between the biological half-life (T /2) of a labeled bile acid, the transit 
time and the faecal weight was studied in the group of patients with a reliable test re-
sult (minimally 20 markers recovered). 
Table VII. Spearman Rank correlations between T 12 and faecal weight (Rl) and rank correlations 
between T 12 and transit time (R2) at different times. 
T/2 vs Faecal weight T/2 VS Transit Time 
n= Rl p-value R2 p-value 
Before RT (B) 25 • 0.56 < 0.01 0.14 n.s. 
EndRT(E) 10 • 0.77 < 0.05 0.42 n.s. 
6Weeks (P) 12 - 0.73 < 0.01 0.81 < 0.01 
6Months (C) 10 - 0.67 < 0.05 0.50 n.s. 
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A clear correlation was found between tbe T 12 and the faecal weight botb before 
and ater the irradiation. A shorter T /2 was associated with a higher faecal weight. 
Remarkebly, no relation could be found between the T 12 and the transit time, with 
the exception of the measurement at six weeks after the irradiation (see table VII). 
4.11 Relation between acute reactions and other factors and tests. 
4.11.1. Relation between acute reactions and patient risk factors. 
The relation between the increase in stool frequency and in "diarrhea factor" and 
the presence or absence of patient risk factors is shown in table VIII below. 
Table VIII. Relation between acute radiation reactions and patient risk factors. (.6. = increase). 
n= 6 Stool D "Diarrhea factor" 
frequency 
Abdominal surgery: 
Absent 48 0.85 0.27 
Present 128 0.88 n.s. 0.25 n.s. 
Diabetis mellitus: 
Absent 162 0.88 0,26 
Present 14 0.72 n.s. 0.20 n.s. 
Cardiovascular 
disease: 
Absent 144 0.92 0.28 
Present 32 0.65 n.s. 0.15 
(p < 0.01) 
Table IX shows the correlation of the age and body build related factors with the in-
crease in stool frequency and in "diarrhea factor". 
Table IX. Relation between acute radiation reactions and patient risk factors (.6 = increase). 
6 Stool frequency !:::. "Diarrhea factor" n= 
Age - 0.02 - 0.05 n.s. 176 
Heigbt - 0.03 - 0.05 n.s: 168 
Weight - 0.12 • 0.18 (p < 0.05) 172 
AP diameter - 0.12 • 0.17 (p < 0.05) 175 
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Alto ugh on visual inspection of the scatter plots a broad variation was observed, on 
analysis in obese patients a marginally significant tendency (p < 0.05) was noted 
towards a smaller increase in stool frequency and "diarrhea factor" on irradiation. 
Except for patients with cardiovascular disease, where tbe increase in "diarrhea 
factor" was smaller than for patients without cardiovascular disease (p < 0.01), no 
relation between the presence or absence of the patient risk factors and the acute 
radiation reactions was observed. 
4.11.2. Reliltion between acute reactions and radiotherapy risk factors. 
Table X shows the increase of stool frequency and of "diarrhea factor" for the 
main radiotherapy risk factors. 
Table X. Relation between acute radiation reactions and radiotherapy risk factor. 
n = Stool frequency ''Diarrhea factor'' 
mean ± s.d. mean± s.d. 
Total delivered dose: 
<50 Gy 79 1.07 (1.06) } 0.33 (0.27) } 
=50 Gy 71 0. 74 (0.86) (p < 0.05) 0.21 (0.24) (p < 0.01) 
>50 Gy 26 0.63 (0.73) 0.18 (0.21) 
Dose per fraction: 
1.8 Gy 27 0.76 (0.80) } n.s. 0.25 (0.23) } n.s. 
2.0 Gy 143 0.89 (0.97) 0.27 (0.26) 
Total treatment time: 
< 43 days 64 0.67 (0.80) I n.s. 0.24 (0.24) I n.s. 44-54 days 62 1.04 (0.93) 0.24 (0.26) 
> 55 days 50 0.91 (1.12) 0.30 (0.28) 
Dose rate: 
high !51 0.90 (0.98) } n.s. 0.27 (0.25) } n.s. 
low 17 0.82 (0.75) 0.14 (0.28) 
A correlation was observed between the increase in stool frequency (p < 0.05) and the increase in ''diarrhea 
factor" (p < 0.01) on the one side and the total delivered dose on the other hand. Increasing the doses of 
radiation resulted in a smaller increase of stool frequency and of ''diarrhea factor''. No other correlations 
were found between the acute radiation reactions and the radiotherapy risk factors. 
4.11.3. Reliltion between acute reactions and test results. 
The correlations between the increase of stool frequency and of "diarrhea factor" 
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with the changes in serum bile acids (fasting and 2 hour postprandial concen-
trations, postprandial increase and the absolute values at the beginning (B), midway 
(H) and at the end (E) of irradiation), varied between- 0.17 and 0.06. 
Thus these values did not indicate any correlation between the acute radiation reac-
tions and the results of our tests. 
4.12. Relation between "late" effects and other factors and tests. 
4.12.1. Relation between "late" effects and patient risk factors. 
Table XI shows the mean value for the age and body build related factors in patients 
with or without late effects. 
Table XL Relation between "late" effects and patient risk factors. 
Late effects No late effects 
n~ mean n~ mean 
Age 59 61 yrs 134 59 yrs 
Height 57 162cm 128 162,3 em 
Weight 58 69.2 kg 131 69.0 kg 
AP diameter 58 21.9cm 134 22.0 em 
No significant differences were observed between patient characteristics in the groups with or without late 
effects. 
Table XII shows the incidence of patient risk factors in the absence or presence of 
late effects. 
Table XII. Relation between "late" effects and patient risk factors. 
Late effects No late effects 
n~ "lo n~ "7o 
Abdominal surgery 59 71 134 72 
Diabetes mellitus 59 11.9 134 7.5 
Cardiovascular disease 59 22 134 17 
No significant differences were observed. 
In conclusion: no relation between the absence or presence of late effects and the 
patient risk factors could be observed. 
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4.12.2. Relation between "late" effects and diet history. 
The development of the "late" radiation effects showed no relation with the diet 
history as analysed from the food intake (relative composition, proteins, carbo· 
hydrates, fat, etc.). 
4.12.3. Relation "late" effects and radiotherapy risk factors. 
The development of "late" effects showed no relation with the radiotherapy factors 
investigated. Variations in the total delivered dose of external irradiation, the total 
treatment time, the dose per fraction, the treatment volume, the radiation technique 
and the kind of intracavitary irradiation and the dose rate of the intracavitary ir· 
radiation had no measurable influence on the development of "late" effects. 
The following table shows the mean values ( ± standard deviation) for the calcula· 
ted TDF and L·Q values for patients with and without "late" effects. 
Table XIII Radiation dose (expressed as TDF or L-Q) in relation to the presence or absence of .. late" 
effects. 
TDF point A 
TDF gut 
L·Q point A early 
L·Q point A late 
L·Q gut early 
L·Q gut late 
TDF "" Time-Dose-Fractionation 
L-Q = Linear-Quadratic 
Late effects 
n= 
94.9 ± 22.1 29 
81.0 ± 11.8 24 
100.3 ± 20.9 29 
I 10.3 ± 32.3 29 
86.7 ± 10.6 27 
88.6 ± 17 27 
No late effects Difference 
n= 
92.5 ± 22.2 58 n.s. 
79.2 ± 8.7 47 n.s. 
96.6 ± 17.3 62 n.s. 
104 ± 28.3 62 n.s. 
84.3 ± 8.7 49 n.s. 
85.5 ± 12.7 49 n.s. 
No relation could be demonstrated between the radiation dose and the development 
of "late" effects, regardless of the mode in which the dose was expressed (TDF or L-Q). 
4.12.4. Relation between ""late" effects (changes in bowel habits) and test results. 
4.12.4.1. Serum bile acid concentrations: the median fasting concentrations at the 
beginning of (B) and at six weeks after (P) the radiotherapy were higher (p = 0.05) 
for the patients developing "late" effects. The median postprandial bile acid con-
centrations at six weeks (P) and 6 months (C) after radiotherapy were higher (p 
0.05) for the patients developing "late" effects (diarrhea) (Fig. 19). 
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Fig. 19: Serial serum bile acid levels during and after pelvic radiotherapy. Fasting (o') and 2 hour post-
prandial (120') values at different times according to the occurence of "late" effects ( + or -) 
(median values and interquartile ranges; abbreviations see legend fig. 7). 
4.12.4.2. Faecal bile acid excretion: the number of patients with a reliable test result 
was too small to assess a possible relation between the bile acid loss and the later 
development of diarrhea. 
4.12.4.3. Faecal weight: no relation was observed between the development of 
"late" effects and the mean of faecal weight at any sampling time. 
4.12.4.4. Transit time: prior to the irradiation, patients, who will develop "late" ef-
fects, have a shorter mean transit time (1.8 versus 2.2, p = 0.02). However, at the 
end of the irradiation and later, no difference in transit time was observed between 
patients with and without "late" effects. 
4.12.4.5. Continence test: the continence test performed prior to the irradiation ap-
peared to have no predictive value for the development of "late" effects. The entire 
range of total leaked volume (from no leakage to leakage of all infused saline) was 
found in patients who developed symptoms as well as in those who did not. 
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4.13. Relation between changes in stool habits and in faecal continence and 
testresults. 
Based on the follow-up data, the entire group of patients was divided into four sub-
groups: 
I) unchanged or hardly changed stool habit with unchanged or hardly changed con-
tinence; 
b) unchanged or hardly changed stool habit with clearly changed continence; 
c) clearly changed stool habit with unchanged or hardly changed continence; 
d) clearly changed stool habit with clearly changed continence. 
(the scoring system for changes in stool habits and changes in faecal continence is 
given in paragraphs 3.5.7.2. and 3.5.8.). 
Table XIV shows the number of patients in the different subgroups. 
Table XIV : patient population divided into the 4 subgroups (a-d) according to changes in stool habits 
and in faecal continence. These patients had a continence test prior to irradiation. 
Faecal continence 
Unchanged Changed 
a b 
Stool habits Unchanged 38 18 
Changed 10 32 
c d 
This table shows that there is only a weak correlation between unchanged stool ha-
bits and unchanged continence and between changed stool habits and changed 
continence. The differences were not significant. 
The test results for the 4 subgroups were then analysed separately. 
4.13.1. Serum bile acid concentrations. No clear difference was observed between 
the 4 subgroups concerning serum bile acid concentrations either before or after the 
irradiation. 
4.13.2. Faecal bile acid excretion. The number of patients was too small to divide 
into 4 subgroups. 
4.13.3. Faecal weight. As shown in the following tables, no differences were ob-
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served in faecal weight between the 4 subgroups either before or after the irradiation. 
Also, there was no increase in faecal weight for any subgroup after the irradiation. 
Table XV: Faecal weight (in grams) before and at 6 months after the irradiation for the four subgroups 
a~d (median values and interquartile ranges). 
Stool weight (grams) 
Before irradiation 6 months after irradiation 
a n= 15 n= 14 b a n = 12 n = 12 b 
110g 140 g 100 g 140 g 
(70-130) (90-210) (80-140) (90-190) 
110g !30g 90 g 120 g 
(100-140) (100-160) (70-100) (80-150) 
c n = 8 n = 23 d c n=7 d n = 17 
4.13.4. Transit time. As shown in the following tables, only slight differences in the 
median value of the transit time were observed before as well as after the ir-
radiation. No clear change and specifically no decreases in transit time were found 
for the four subgroups after the irradiation. 
Table XVI: Transit time in days before and at 6 months after irradiation for the four subgroups a·d 
(median values and interquartile ranges). 
Transit Time (days) 
Before irradiation 6 months after irradiation 
a n= 14 n= 14 b a n = 9 n = 12 b 
1.9 1.5 2.0 1.6 
(1.5-2.5) (1.4-2.8) (1.5-2.4) (1.2-1.8) 
1.8 1.6 2.6 1.9 
(1.5-2.1) (1.2-2.1) (1.8-2.8) (1.8-2.4) 
c n=7 n = 22 d c n = 4 n = 13 d 
4.13.5. Continence test. The median value for the total leaked volume for the four 
subgroups, a-d are shown in the following table. Apart from a slightly lower median 
value for group c (n.s.), no differences were observed between the subgroups. 
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Table XVII: Total leaked volume for the four subgroups a-d (median values and interquartile ranges). 
Faecal continence 
Unchanged Changed 
a b 
Unchanged 1110 1200 
Stool habits (660-1275 (1095-1380 
Changed 525 1005 
(210-1245) (360-1305) 
c d 
4.14. Relation between acute and "late" effects. 
We observed a difference in the acute effects, mean stool frequency and consistency 
among patients who subsequently experienced "late" effects and those who did not. 
Fig. 20 shows the change in mean stool frequency during therapy for both groups. 
Furthermore, 250Jo of the patients who dit not develop "late" effects dit not notice 
any change in stool frequency, while in those developing late effects a! had an 
increased stool frequency outside the normal range during the irradiation period. 
Fig. 21 shows the change in "diarrhea factor" for the two groups. During the first 3 
weeks of radiotherapy, a difference in "diarrhea factor" was observed between 
patients who subsequently experienced "late" effects and those who dit not. 
RELATION BETWEEN EARLY AND "LATE" EFFECTS. 
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Fig. 20: Changes in stool frequency during radiotherapy, according to the occurrence of "late" effects 
( + or - ). 
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Fig. 21: Changes in "diarrhea factor" during radiotherapy according to the occurrence of "late" effects 
(+or-). 
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CHAPTERV 
DISCUSSION 
5.1. Introduction. 
Radiotherapy of the pelvic region is a generally accepted treatment for malignant 
tumours of the uterus. 
This treatment, however, is not without side-effects. The most important com-
plaints involve the gastrointestinal tract. They include diarrhea, rectal blood loss an 
faecal incontinence. In a small number of patients, severe complications, mainly 
fistulas and stenoses will develop. 
Apart from these side-effects, urinary tract symptoms arise. However, consider-
ation of these side-effects is beyond the scope of this study. 
In the present study one-hundred and ninety-six patients, irradiated for a gynaeco-
logical malignancy in the Rotterdamsch Radio-Therapeutisch Instituut were prospec-
tively followed-up in order to elucidate the incidence and pathophysiology of chan-
ges in stool habits in relation to the radiotherapy applied. 
Such clinical symptoms are usually divided into acute radiation reactions and late 
effects. 
In the literature, late effects are often defined as fistulas and/ or stenoses. They 
sometimes develop after a long latent period, ranging up to several years. 
A direct relation between acute and late effects is often denied on a priori grounds in 
the literature, on the assumption that the mechanism of development of both types 
of effects is different. Acute effects are thought to be the result of epithelial dam-
age, while late effects would be caused by damage to blood vessels and connective 
tissue. 
In our study, with a limited follow-up time, only four patients with severe late 
effects (intestinal fistulas, stenoses) were observed. These patients were not analysed 
separately. 
As our study was directed towards the milder syndrome of diarrhea and faecal 
incontinence, the "late" effects as defined in our study differ fundamentally from 
the above-mentioned severe complications. 
71 
We defined "late" effects as a change in bowel habits. This could be an increase in 
stool frequency and/ or a change in stool consistency as well as faecal incontinence 
developing or continuing during the follow-up period. 
5.2. Radiotherapy factors. 
To begin with. we studied the influence of radiotherapy factors on the incidence of 
acute and "late" effects. 
Acoording to the literature. there are several radiotherapy factors that might play a 
role in the development of these symptoms (Chapter l). A number of these factors 
was investigated by us: 
I) the total delivered dose of external irradiation; 
2) the total treatment time; 
3) the dose per fraction; 
4) the dose rate of the intracavitary irradiation; 
5) the combined doses of external and intracavitary irradiation (expressed as Time-
Dose-Fractionation (TDF) or Linear-Quadratic (L-Q) number). 
The clinical symptoms showed no relation with any of the above-mentioned radio-
therapy factors, with the exception of the total delivered dose of external irradiati-
on. When this dose increased, the increase in stool frequency and in "diarrhea factor" 
was less pronounced. This is contracdictory to what was expected. The explanation 
might be that the higher doses were given with a different fractionation schedule 
(smaller dose per fraction, longer total treatment time). However, no significant dif-
ferences were observed for these other factors. No relation was observed between 
the total dose and the "late" effects. A possible explanation is that the radiotherapy 
schedules applied differ only very little, thus great differences in side-effects were 
not to be expected. Moreover, in the case of external irradiation, the differences in 
total dose, total treatment time and dose per fraction are not independent from each 
other but interrelated. The reason for this interrelation is that the treatment sched-
ules aim at an equal biological effect. However, the difference in the dose of intra-
cavitary irradiation was not dependent on other radiotherapy factors, but only on the 
diagnosis: patients treated for a carcinoma of the uterine cervix (exclusive radio-
therapy) receive a higher dose of intracavitary irradiation than do patients treated 
postoperatively for a carcinoma of the uterine cervix or of the endometrium. These 
differences in intracavitary irradiation were not reflected in clinical symptoms in our 
study. One should bear in mind that, with intracavitary irradiation, the dose 
gradient (the decrease in radiation dose at increasing distance from the source) is 
steep. This implies that high doses of radiation are merely limited to small volumes 
of tissue. 
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5.3. Patient factors. 
If the (small) differences in the radiotherapy applied have no influence on the devel-
opment of damage, are there perhaps patient-related factors (risk factors) which do 
have an impact? 
According to the literature, there are several risk factors for the development of 
bowel damage (Chapter 1). 
These can be divided into two groups, of which the following factors were investi-
gated by us: 
A) age; 
height and weight; 
diabetes mellitus; 
possible cardiovascular disease; 
B) previous abdominal surgery, especially gynaecological operations, cholecystecto-
my and gastrointestinal surgery. 
The incidence of the clinical symptoms showed no correlation with these factors 
with the exception of cardiovascular disease where in the precense of this history the 
increase in "diarrhea factor" was smaller. No relation with the increase in stool 
frequency was observed. Also obese patients tended to have less acute reactions. 
No relation between these patient factors and the "late" effects was observed. In the 
literature, a pre-existent vascular change is assumed to be the underlying cause of 
these so-called risk factors (A) (7, 14, 15). The syndrome studied by us (acute as well 
as "late") did not show a correlation with any of these "risk factors", suggesting 
a pre-existent vascular change did not play a role. 
Previous abdominal surgery (B), especially of the pelvic region, would lead to fixed 
loops of intestine and therefore result in higher doses of radiation to the individual 
intestinal segments. Postoperative fixations might thus play a role in the develop-
ment of fistulas and stenoses. In our opinion, the assumption that in patients with 
previous abdominal surgery the loops of small intestine fixed by postsurgical ad-
hesions would be unable to withdraw themselves from radiation damage, has to be 
questioned. On X-ray examination of the intestine after administration of a barium 
meal, a constant position of the intestine with regard to the source was observed 
during several intracavitary irradiations in patients with and without previous surgery. 
It is quite possible that radiotherapy itself causes adhesions at an early stage. 
The clinical symptoms also showed no relation with the diet history of the patients 
before the irradiation. In theory the advice given by the dietitian to symptomatic 
patients could have influenced clinical symptoms. However this advice was only 
given after the symptoms had been recorded so that this advice is unlikely to have 
influenced these symptoms. 
The test results after the irradiation period may have been influenced by advised or 
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self prescribed changes in diet. However, this was not studied. In summary, the 
individual sensitivity of the patients to radiation is a more important factor for the 
eventual development of radiation damage than the combined doses of external and 
intracavitary irradiation. 
This individual sensitivity, however, was not reflected in the risk factors which we 
studied. 
5.4. Clinical symptoms. 
During and after radiotherapy for a gynaecological malignancy, patients often 
developed diarrhea and faecal incontinence. 
To explain these phenomena the following hypothesis was formed: 
Irradiation of the bowel leads to damage of the intestinal mucosa. In the ileum, 
this will result in impaired bile acid reabsorption, which in turn results in an in-
creased spillover of bile acids into the colon, leading to "cholerheic" diarrhea. 
This diarrhea, in combination with a pre-existent insufficient continence mech-
anism, will give rise to the clinical syndrome. 
In order to test this hypothesis the following items were investigated before, during 
and after the irradiation: 
I) stool habits (anamnestic); 
2) the bile acid concentrations in the serum, fasting and 2 hours after a test meal; 
3) the biological half-life of a tracer dose of labeled cholic acid; 
4) mean daily faecal weight (collecting period, 4 days); 
5) mean intestinal transit time; 
6) the ability to retain a rectal infusion of normal saline (continence test according 
to Read (81), only before the irradiation). 
What were the results of these tests and how did they correlate with the clinical 
symptoms? 
5.4.1. Acute reactions. 
During the irradiation, about 75% of the patients experienced diarrhea, i.e., watery 
stools and an increase in stool frequency. This was associated with an increase in 
mean faecal weight. It is important, however, that the transit time, that is mainly the 
time of the passage through the colon, remained unchanged. The bile acid concen-
trations in the serum showed a significant decrease during irradiation. This is in 
agreement with the shortening of the biological half-life (T /2) of an administered 
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tracer dose of bile acids (in a subgroup of patients), indicating an increased loss of 
bile acids due to impaired reabsorption. 
A relation was shown to exist between the T /2 and the faecal weight at all sampling 
times (B, E, P and C), a shorter T /2 being associated with a higher faecal weight. 
On first sight, the test results for the entire group of patients seem to be in agree-
ment with our hypothesis that the diarrhea was caused by increased faecal loss of 
bile acids. 
For the group as a whole the median serum bile acid concentrations fell signifi-
cantly, while the faecal weight and the stool frequency rose. 
There was, however, in the individual patient no relation between the magnitude of 
the fall in bile acid concentration and the increase in faecal weight as well as the 
most important complaint of the patients, the increase in stool frequency. 
This suggested that another factor, probably a local one in the rectosigmoid, caused 
the changes in stool frequency. 
The absence of a clear relation between the loss of bile acids and the stool frequency 
in the individual patient is in agreement with the results of Stryker (64), who ob-
served an increase in stool frequency without a direct relation with the decrease in 
cholic acid concentrations in the serum. 
5.4.2. "Late" effects. 
In the months following irradiation, a substantial number of patients developed or 
continued to have complaints of diarrhea and of some faecal incontinence. Accord-
ing to their histories, 59/185 patients (30"7o) experienced these symptoms. Newman 
(1973) reported a considerably higher percentage of changes in stool habits, 70%, in 
17 patients. But, in his relatively small study, several irradiation techniques were 
used and therefore the study cannot be compared with ours. 
No other prospective studies into the incidence of postirradiation diarrhea have 
been published. Our findings indicate that the evidence of this distressing side-effect 
is far more frequent than in generally assumed. In our study, we found a distinct re-
lation between the "late" effects and previously experienced acute reactions. All pa-
tients who developed "late" effects showed an increased stool frequency during the 
irradiation. In addition, the mean stool frequency of patients who developed "late" 
effects was significantly higher than for those whithout "late" effects. 
5.5. Intestinal function tests. 
Are these symptoms related to changes which we observed in the intestinal function 
tests? 
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In the period after the irradiation, the bile acid concentrations in the serum* and the 
mean faecal weight returned to normaL The transit time remained unchanged, also 
during the follow-up period, as it did during the acute phase (5.4.!.). 
Before going further into the possible relation between the complaints on the one 
hand and the observed changes in bile acid metabolism on the other, we will first 
pay attention to the question: How can one explain the recovery of the bile acid con-
centration in the serum after completion of the irradiation? 
Two possible explanations are suggested: 
l) The damage to the ileal mucosa is completely repaired. The reabsorption of bile 
acids is again normaL Subsequently the amount of bile acids presented to the liver 
also has become normal again and the spillover of bile acids into the colon is re-
duced to its normal low leveL In agreement with this would be the return of the 
faecal weight to its preirradiation leveL Observations to refute this view have not 
been made by us apart from the shortened biological half-life of cholic acid 
found 6 months after the irradiation. 
2) The damage to the mucous membranes of the ileum is not repaired or incom-
pletely so. In favour of this suggestion is the fact that the biological half-life is still 
shortened at 6 months after the irradiation, indicating significant bile acid loss. 
The fact that the bile acid concentration in the serum becomes normal again in 
spite of this incomplete repair would then have to be explained by an increased 
bile acid secretion, implicating increased de novo synthesis in the liver. As a 
result, in spite of a lower rate of reabsorption in the ileum, the ultimate supply by 
portal venous blood remains the sarne. Evidently, there will also be increased 
faecal loss of bile acids. This last phenomenon was not investigated by us, but it was 
one of the findings in the study of Van Blankenstein (84). The observations that 
the fasting concentration of bile acids had recovered during the second half of 
the irradiation period and that the 2-hour postprandial bile acid concentration 
did not further decrease, plead in favour of an adaptation of bile acid secretion 
by the liver, by de novo synthesis. 
Therefore, the bile acid concentration in the serum after irradiation may reflect a 
new steady state of the enterohepatic circulation (EHC) on a higher level of se-
cretion by the liver. 
The return of the faecal weight to its pretreatment level, however, indicates that the 
additional loss of bile acids cannot be very great**; for severe loss of bile acids 
would result in a marked increase in faecal weight. 
*An unexplained observation, which we report for the sake of completeness, is that the bile acid concen~ 
!rations in the serum of patients who developed "late" effects appeared to be (marginally) higher than 
in patients without "late'' effects. 
**Possibly, the change in stool consistency can be attributed to a slight increase in faecal bile acids. 
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In what other way can we determine changes in bile acid metabolism? 
A number of investigators used the bile acid breath test for this purpose. With this 
test, the bacterial degradation of bile acids in the large intestine (sometimes the 
small intestine) is estimated by means of the exhaled C02 labeled with a tracer dose 
of I4C (par. 2.5.2.3.). 
Newman (13) found an abnormal breath test in 16 out of 17 patients after pelvic ir-
radiation, but he did not perform the test before the irradiation. Stryker (63) found 
that, by the end of the irradiation, one-third of the patients showed an abnormal 
breath test, which nevertheless recovered in most cases. He did not find a corre-
lation between an abnormal breath test and the stool frequency. A relation between 
an abnormal breath test and diarrhea during the follow-up period was not reported 
by him. We did not use the bile acid breath test in our study. 
Van Blankenstein (84) studied patients who experienced diarrhea during postir-
radiation follow-up and found an abnormal bile acid breath test as well as a 
shortened biological half-life, without, however, the expected marked increase in 
faecal weight. 1n our study, we could confirm the shortening of the biological half-
life of a tracer dose of cholic acid after irradiation, this shortening only partly 
recovered. Based on the findings that 1) the bile acid concentrations in the serum 
recovered in spite of the development of "late" effects and 2) that the faecal weight 
did not increase, the hypothesis that impaired reabsorption of bile acids is respon-
sible for the "late" effects had to be rejected. 
The second part of our hypothesis was that a continence mechanism that was already 
weak before irradiation, can be demonstrated by the reefal normal saline retenti-
on test according to Read (81), would predict the probability of developing faecal in-
continence after irradiation. One should bear in mind that Read investigated the 
mechanism of incontinence in a totally different group of patients. None of these 
patients had been irradiated previously. Based on our results with Read's test, it ap-
peared to have no predictive value for the development of incontinence in our ir-
radiated patients. Even in patients who experienced watery stool during the follow-up 
period (regardless whether they were able to retain a saline enema or not). Read's 
test does not predict whether faecal incontinence will occur after irradiation. The 
second part of the hypothesis, that a weak sphincter mechanism predicts postir-
radiation incontinence, also had to be rejected. 
On the basis of the observed "late" effects, of a changed or unchanged stool habit 
and of a changed or unchanged faecal incontinence, the following four subgroups 
were distinguished: 
I) no diarrhea, continent; 
2) no diarrhea, incontinent; 
3) diarrhea, continent; 
4) diarrhea, incontinent. 
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Contrary to our expectations, no differences between the four subgroups could be 
demonstrated in either serum bile acid levels, intestinal transit time or continence 
tests. 
This holds for the tests performed at the beginning of the irradiatio as well as at 6 
months afterwards. (The continence test was not repeated). Although no difference 
in bile acid metabolism among the four subgroups could be found, either before or 
6 months after the irradiation, the possibility had to be excluded that the test results 
of the entire group had changed in the course of 6 months. This also did not appear 
to be the case. In other words, as a number of patients developed diarrhea and 
incontinence, these complaints arose in spite of unchanged transit time, faecal 
weight and bile acid concentrations in the serum. 
The fact that a number of patients developed diarrhea in spite of a transit time that 
did not change, seems surprising at first sight. As the small intestinal transit time is 
short and relatively constant, the transit time is mainly determined by the transit 
from the coecum to the anus. During transport in the colon two periods can be dis-
tinguished. The coecum to sigmoid time and the time that the faeces is stored in the 
rectosigmoid reservoir. (When the mean stool frequency is once a day, the sigmoid 
to anus time is maximally 24 hours). 
The unchanged transit time can be based on an unchanged coecum-sigmoid time. 
Although the sigmoid-anus time would also be shortened as a result of an increased 
stool frequency, this cannot be detected with the collection of the stools in 24-hour 
portions as applied. 
When neither an increased faecal weight (e.g., on account of an increased loss of 
bile acids) nor a pre-existent insufficient continence mechanism nor a shortened 
transit time can explain the observed diarrhea and incontinence, what then can be 
the cause? 
Based on the above-mentioned considerations, we think that the cause has to be 
found in local damage to the rectosigmoid reservoir (Par. 2.8.), by which the ca-
pacity to store the faeces for a longer period is lost. This can be accompanied by an 
imperative urge and faecal incontinence, the latter not being predicted by a conti-
nence test. Besides, it is likely that the relaxation of the internal sphincter, which 
originates by a local and spinal reflex activity when the pressure inside the rectum 
increases, already occurs at a lower faecal volume, as the compliance of the rectal 
wall is diminished. This assumption is in agreement with the results of Touchais (82) 
who showed that the distensibility of the irradiated rectum was decreased. 
5.6. Conclusions. 
The late effects after pelvic irradiation (diarrhea and incontinence) which we studied, 
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have to be attributed to an impaired reservoir function of the rectosigmoid due to 
direct radiation damage. 
A relation with the bile acid metabolism and continence test according to Read as 
studied by us could not be demonstrated. 
The "late" effects which we studied were especially seen in the group of patients 
which showed severe acute rections. The severe late effects (stenoses and fistulas) 
are exceptional with the radiotherapy schedules applied and cannot be predicted on 
the basis of the relatively mild. acute and "late" effects that we observed. 
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SUMMARY 
Radiotherapy can be applied in two ways: 
I) by external beam irradiation; 
2) by intracavitary or interstitial irradiation. 
For the irradiation of a gynaecological tumour the combination of the two is used. 
With external irradiation by orthovoltage machines, the dose which can be given is 
limited by damage to the skin. When orthovoltage therapy was replaced by mega-
voltage therapy, skin damage was no longer a limiting factor. It thus became possi-
ble to deliver an adequate dose to deep-seated tumours. At the same time, it was 
possible to irradiate larger volumes. Formerly, only the parametria were irradiated; 
now, it became possible to include the regional lymph nodes. This led to the possi-
bility that damage to other organs, e.g., the intestine became the dose limiting factor. 
Intracavitary irradiation with radioactive sources has also played an important role, 
especially in the irradiation of malignant tumours of the uterus. Of imporrance is 
the steep dose gradient, which means the rapidly decreasing radiation density at 
increasing distance from the sources, around these intracavitary sources. This 
results in an inhomogeneous dose distribution within the target volume and may lead 
to locally high doses of absorbed radiation in normal tissues situated within this tar-
get volume. The serious complications such as stenoses and fistulas as described in 
the literature are mainly the results of these local high doses. The incidence of these 
serious complications is relatively low, 5-!0o/o, with modern radiotherapy. A 
prospective study of these serious complications will therefore only be possible with 
a large number of patients. Yet, to get an impression of the undesirable side-effects, 
we performed a prospective study into other signs of intestinal damage, namely, a 
change in stool habits, as this is more frequently observed after "gynaecological" 
irradiation. 
In Chapter I, following a general introduction, the risk factors mentioned in the litera-
ture are reviewed. A distinction can be made between patient factors and therapy 
factors. Patient factors are assumed to be based on pre-existent vascular changes 
and fixed intestinal loops after previous abdominal surgery. Therapy factors are the 
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characteristics of the irradiation, such as fractionation schedule, irradiation 
technique and radiation dose. 
In Chapter II, the changes in bowel function after irradiation are reviewed. First, a 
historic review is given; then, the changes in histopathology and function, followed 
by a discussion of the symptoms of this intestinal damage. The main symptoms are 
diarrhea and faecal incontinence. Several investigators have pointed out the role 
that the bile acid metabolism could play in the occurrence of this irradiation diar-
rhea. 
In the second part of Chapter II, this bile acid metabolism is further explained: The 
enterohepatic circulation (EHC) of bile acids is very efficient under physiological 
circumstances. Only a small part of the bile acids is lost by the faecal route. The liver 
clears almost all bile acids presented to it by portal venous blood; only a very small 
fraction will pass and is detectable in the peripheral blood serum. The different 
methods for studying the EHC of bile acids are described. The pathophysiology of 
an interrupted EHC of bile acids is then reviewed. If bile acids are not reabsorbed 
by the terminal ileum, they reach the colon where they can cause diarrhea. An inter-
ruption of the EHC as a result of radaition damage might play a role in the 
symptoms. 
The study design is discussed in Chapter III. 
The working hypothesis consisted of two parts: 
I) Irradiation on the pelvic region leads to damage of the ileal mucosa which results 
in an interruption of the EHC of bile acids. The following increased spillover of 
bile acids into the colon induces water and NaCI secretion by the colonic mu-
cosa. This is expressed as diarrhea. 
2) There existed a pre-existent insufficient continence mechanism, which could be 
demonstrated by means of a rectal retention test with saline according to Read. 
The combination of these two phenomena was assumed to be the cause of the clini-
cal symptoms of diarrhea and faecal incontinence after pelvic irradiation. This 
hypothesis was tested in a group of patients who were irradiated for a malignant 
tumour of the uterus. The irradiation was given as the only treatment modality or as 
a supplement following surgery. 
Before, during and after the irradiation, several tests were performed, viz., bile acid 
concentrations in the serum, biological half-life of a radioactively labeled tracer 
dose of cholic acid, mean faecal weight, intestinal transit time and a continence 
test (the continence test only before the irradiation). In addition, the nature and 
frequency of the bowel motions were recorded: daily during the irradiation and at 
every visit during the follow-up period. 
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In the second part of Chapter l!I, the methods of irradiation and the performance 
of the tests are discussed. 
The results of the study are discussed in Chapter IV. During the irradiation, a 
decrease in bile acid concentrations in the blood serum occured. The biological half-
life was also shortened. Both phenomena suggest the loss of bile acids. At the same 
time, the mean faecal weight increased. The intestinal transit time, however, ap-
peared not to change. The stool frequency increased and the stools became watery. 
This seems in agreement with our working hypothesis that spillover of bile acids is 
responsible for the diarrhea. After the irradiation, the bile acid concentrations in the 
serum and the mean faecal weight recovered. The biological half-life of bile acids, 
however, remains shortened after an initial recovery. The transit time remained 
unchanged, also during the follow-up period. The diarrhea during the irradiation 
subsided in most of the patients. Still, in about 300Jo of the patients, a changed stool 
habit persisted or developed during the follow-up period. 
If a smaller group of patients was investigated by means of a questionnaire, even 
500Jo appeared to be less capable of retaining their faeces than before. 
Discussion and Conclusions are given in Chapter V. The fact that no dose-effect 
relationship was found between the dose of radiation applied and the incidence and 
the severity of the observed clinical symptoms can be explained by the small spread 
in external radiation dose applied. The difference in intracavitary irradiation also 
did not influence the development of the clinical symptoms. Probably, the individual 
sensitivity to radiation is more important than the small differences in radiation 
doses. The "risk factors" mentioned in the literature also appeared to have no 
influence on the development of the clinical symptoms. 
Although within the narrow margins of modern radiotherapy, neither the differ-
ences in external, nor in intracavitary doses of radiation appeared to have influence 
on the development of the symptoms and although the symptoms did not correlate 
with any of the so-called patient factors, the fact remains that a considerable 
number of patients did complain about changes in stool habits and/ or incontinence 
after the irradiation. In view of the demonstrated changes in bile acid metabolism after 
irradiation, we investigated whether these changes might be the cause of the diarrhea 
or at least demonstrate a statistical correlation therewith. 
Between the groups who did or did not develop these complaints, no differences in 
bile acid concentrations in the serum, mean faecal weight or transit time could be 
demonstrated either before or at 6 months after the irradiation. Also, there was no 
significant change in the test results at 6 months after the irradiation. 
The incapacity to retain a considerable amount of 0.90Jo NaCl in the rectum during 
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the continence test according to Read, did not appear to be predictive for the devel-
opment of faecal incontinence during the follow-up period. 
Consequently, the hypothesis that diarrhea and incontinence after irradiation are 
the results of a combination of impaired reabsorption of bile acids in the small 
intestine and a weak "sphincter mechanism" had to be rejected. The observed chan-
ges in bile acid metabolism as a result of the irradiation (decreased bile acid concen-
trations in the serum and a shortened biological half-life) have to be explained by 
damage to the ileal mucosa during the irradiation, followed by a partial recovery. 
Adaptation of the bile acid secretion by the liver, especially as a result of increased 
de novo synthesis, explains the recovery of the bile acid concentrations in the serum 
in spite of accelerated loss by the intestine. The unchanged transit time seems surpris-
ing at first sight. However, the transit time is determined mainly by the coecum-
anus time. With a coecum-sigmoid time which remained the same, an eventual shorte-
ning of the sigmoid-anus time could be easily unnoticed in our study, as the collec-
tion of the stools (and the administered markers) took place in 24-hour portions. 
Based on our study, we have to conclude that the bowel complaints of patients after 
"gynaecological" pelvic irradiation are caused by an impaired capacity for reten-
tion of faeces of the "rectosigmoid reservoir" as a direct result of the irradiation. 
Therefore, an in itself not increased amount of faeces is excreted in several portions. 
This is accompanied by imperative urge, leading to faecal incontinence. 
84 
SAMENV ATTING 
Radiotherapie kan op 2 wijzen toegediend worden: 
a) door uitwendige bestraling of 
b) door inwendige bestraling. 
Voor de bestraling van gynaecologische tum oren wordt de combinatie van beide ge-
bruikt. 
Bij uitwendige bestraling met orthovoltapparatuur wordt de dosis die kan worden 
toegediend beperkt door beschadiging van de huid. Bij overgang van ortho- naar 
megavolttberapie was schade van de huid geen beperkende faktor meer. Het werd 
dus mogelijk op dieper gelegen tum oren een adequate bestralingsdosis toe te dienen. 
Tevens werd het mogelijk, grotere volumina te bestralen. Werden voorheen aileen de 
parametria bestraald, nu konden ook de regionale lymfklierstations meebestraald 
worden. Dit leidde ertoe, dat mogelijke schade aan andere organen o.a. de darm de 
dosislimiterende faktor werd. 
Inwendige bestraling met radioaktieve bronnen heeft eveneens een belangrijke 
plaats, met name bij bestraling van kwaadaardige gezwellen van de baarmoeder. 
Van belang hierbij is de steile dosisgradient rondom deze inwendige bronnen, d.w.z. 
dat de stralendichtheid snel afneemt bij toenemende afstand van de bronnen. Dit 
leidt tot inhomogene dosisverdeling binnen het "doelvolume" en kan aanleiding 
zijn tot plaatselijke absorptie van hoge doses straling in "normale" weefsels, indien 
deze binnen het "doelvolume" gelegen zijn. 
De in de literatuur beschreven ernstige complicaties zoals stenosen en fistels, zijn 
voornamelijk het gevolg van deze lokale hoge doses. Het v66rkomen van deze ern-
stige complicaties is met moderne radiotherapie betrekkelijk zeldzaam, 5-IOOJo. 
Een prospectieve studie van deze ernstige complicaties is dan ook slechts mogelijk 
met grote aantallen patienten. Om toch een indruk te krijgen van ongewenste bij-
werkingen, verrichtten wij een prospectief onderzoek naar andere tekenen van be-
schadiging van de darm, namelijk een verandering in het defaecatiepatroon, daar dit 
na "gynaecologische" bestralingen frequent is. 
In Hoofdstuk I worden na een algemene inleiding de in de literatuur genoemde risico-
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faktoren voor het ontstaan van ernstige darmschade besproken. Een onderscheid 
kan gemaakt worden tussen patientenfaktoren en therapiefaktoren. Patientenfak-
toren worden verondersteld te berusten op pre-existente vaatafwijkingen en op ge-
fJXeerde darmlissen na voorafgaande buikoperaties. 
Therapiefaktoren zijn de kenmerken van de bestraling, zoals fractioneringsschema, 
bestralingstechniek en bestralingsdosis. 
In Hoofdstuk li worden de veranderingen in darmfunktie na bestraling besproken. 
Allereerst word! een historisch overzicht gegeven, vervolgens worden de histopatho-
logische en funktionele veranderingen beschreven, gevolgd door een bespreking van 
de symptomen van deze darmbeschadiging. De voornaamste symptomen zijn diar-
rhee en incontinentie voor outlasting. Verschillende onderzoekers hebben gewezen 
op de rol die het galzuurmetabolisme bij het ontstaan van deze bestralingsdiarrhee 
zou kunnen spelen. 
In het tweede gedeelte van hoofdstuk II wordt dit galzuurmetabolisme nader uiteen-
gezet: De enterohepatische cyclus (EHC) van galzuren is onder fysiologische 
omstandigheden zeer efficient. Slechts een klein gedeelte van de galzuren gaat langs 
faecale weg verloren. De lever neemt vrijwel aile galzuren uit het aangeboden 
poortaderbloed op; slechts een zeer kleine fractie wordt "doorgelaten" en is dan 
aantoonbaar in het perifere bloedserum. De verschillende methoden om de EHC 
van galzuren te bestuderen worden aangegeven. 
Vervolgens wordt de pathofysiologie van een onderbroken EHC van galzuren 
besproken. Als galzuren door het terminale ileum niet worden gereabsorbeerd, 
komen zein het colon waar ze diarrhee kunnen veroorzaken. Een onderbreking van 
de EHC ten gevolge van stralenschade van het ileum zou een rol bij de symptomen 
kunnen spelen. 
In Hoofdstuk III wordt de opzet van ons onderzoek besproken. 
De werkhypothese bestond uit twee gedeelten en luidde: 
a) bestraling van het bekkengebied leidt tot beschadiging van het ileumslijmvlies 
metals gevolg een onderbreking van de EHC van galzuren. De hieruit volgende 
vergrote galzuuroverloop naar het colon wekt water en NaCI secretie van het 
colonslijmvlies op. Dit uit zich als diarrhee. 
De tweede component van onze hypothese was: 
b) het bestaan van een pre-existent onvoldoende ''continentiemechanisme'', dat 
d.m.v. een rectale retentietest met fysiologische zoutoplossing volgens Read aan-
getoond zou kunnen worden. 
De combinatie van deze twee componenten werd verondersteld na bekkenbestraling 
het klinische syndroom van diarrhee en incontinentie voor outlasting te veroor-
zaken. Deze hypothese werd getoetst op een groep patienten die bestraald werden 
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i. v .m. een kwaadaardig gezwel van de baarmoeder. Deze bestraling werd deels als 
enige behandelingsmodaliteit of bij andere patienten als aanvulling na operatie toe-
gediend. 
Voorafgaande aan, tijdens en na de bestraling werden verschillende tests uitgevoerd, 
te weten serum galzuurconcentraties, biologische halfwaardetijd van een radioactief 
gelabelde tracerdosis galzuur, gemiddeld ontlastinggewicht en passagetijd door de 
darm, alsmede een continentietest (deze laatste alleen v66r de bestraling). 
Verder werden aard en frequentie van de defaecatie genoteerd; tijdens de bestraling 
dagelijks, gedurende de follow-up periode bij ieder controlebezoek. In het tweede 
gedeelte van hoofdstuk III worden de methoden van de bestraling en de uitvoering 
van de tests besproken. 
In Hoofdstuk IV worden de resultaten van het onderzoek besproken. 
Tijdens de bestraling treed! een daling van de galzuurconcentraties in het bloedse-
rum op. Bovendien blijkt dat de biologische halfwaardetijd van de galzuren is ver-
kort. Beide verschijnselen wijzen op verlies van galzuren. Tevens is er een toename 
van het gemiddelde ontlastinggewicht. De passagetijd door de darm blijkt echter 
niet te veranderen. De defaecatiefrequentie neemt toe en de outlasting word! dun-
ner. Dit lijkt in overeenstemming met onze werkhypothese dat galzuuroverloop 
voor de diarrhee verantwoordelijk is. Na de bestraling herstellen de serum galzuur-
concentraties en het gemiddelde ontlastinggewicht zich. De biologische halfwaarde-
tijd van galzuren blijft echter na een initieel herstel verkort. De passagetijd daaren-
tegen blijft ongewijzigd, ook in de follow-up periode. 
De diarrhee tijdens de bestraling verdwijnt bij het merendeel van de patienten. Toch 
houdt of ontwikkelt van de gehele groep patienten circa 30'7o gedurende de follow-
up een veranderd ontlastingpatroon. 
Indien men echter een kleinere groep via een gerichte enquete ondervraagt, blijkt dat 
zelfs 50'7o de outlasting minder goed op kan houden dan voorheen. 
Discussie en conclusies worden weergegeven in Hoofdstuk V. 
Het feit dat geen dosis-effekt relatie tussen de toegediende dosis rontgenstraling en 
de incidentie zowel als de ernst van de gevonden klinische verschijnselen bestond, 
kan verklaard worden door de geringe spreiding in de dosis stralen die uitwendig 
werd toegepast. Ook het verschil in inwendige bestraling bleek niet van invloed op 
het al dan niet ontstaan van de klinische verschijnselen. Blijkbaar is de individuele 
stralingsgevoeligheid belangrijker dan de geringe verschillen in bestralingsdosering. 
De in de literatuur vermelde "risicofaktoren" bleken evenmin van invloed op het 
ontstaan van de klinische verschijnselen. 
Hoewel binnen de nauwe marges van de modeme radiotherapie verschillen in uit-
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noch inwendige stralendoses van invloed bleken op het a! dan niet ontstaan van 
symptomen en hoewel de symptomen met geen der zogenaamde "patientenfak-
toren" correleerden, doet zich toch het feit voor dat een aanzienlijk aantal patienten 
na de bestraling klachten krijgt en wei verandering van het ontlastingpatroon en/ of 
incontinentie. Gezien de aangetoonde veranderingen in de galzuurstofwisseling na 
bestraling hebben wij onderzocht of deze veranderingen wellicht de oorzaak van de 
diarrhee zouden kunnen zijn, althans daarmee een statistische correlatie zouden ver-
tonen. 
Tussen de groepen die wei of niet deze klachten ontwikkelden kon een verschil in se-
rum galzuurconcentraties, gemiddeld ontlastinggewicht of passagetijd niet worden 
aangetoond, noch voorafgaand aan de bestraling, noch op het tijdstip 6 maanden 
na de bestraling. 
Evenmin bleek er 6 maanden na de bestraling een significante verandering in de 
resultaten van deze tests te zijn opgetreden. 
Een onvermogen om tijdens de continentietest volgens Read een flinke hoeveelheid, 
0.9"7o NaCI, in het rectum vast te houden bleek niet voorspellend voor het a! of niet 
ontstaan van incontinentie voor ontlasting in de follow-up peri ode. Derhalve diende 
de hypothese dat diarrhee en incontinentie na bestraling een gevolg zijn van de com-
binatie van verrninderde reabsorptie van galzuren in de dunne darm met een zwak 
"sfmctermechanisme" verworpen te worden. De aangetoonde veranderingen in bet 
galzuurmetabolisme als gevolg van de bestraling (verlaagde serum galzuurconcen-
traties en verkorte biologische halfwaardetijd), moeten verklaard worden door be-
schadiging van het ileumslijmvlies tijdens de bestraling, gevolgd door een partieel 
herstel. 
Aanpassing van de galzuur secretie door de lever, met name als gevolg van verhoog-
de de novo synthese, verklaart dan het herstel van de galzuurconcentratie in het 
serum, ondanks versneld verlies via de darm. De onveranderde passagetijd lijkt op 
het eerste gezich verrassend. De passagetijd wordt echter voornamelijk bepaald 
door de coecum-anus tijd. Bij een gelijk blijvende coecum-sigmoid tijd kon in ons 
onderzoek een eventuele verkorting in sigmoid-anus tijd echter gemakkelijk onopge-
merkt blijven, aangezien de verzameling van de outlasting (en van de toegediende 
"markers") in porties van 24 uur plaatsvond. Op basis van ons onderzoek moet 
worden geconcludeerd dat de darmklachten van patienten na "gynaecologische" 
bekkenbestraling veroorzaakt worden door een verminderde opslagcapaciteit voor 
faeces van het "rectosigmoid reservoir" als direkt gevolg van de bestraling. 
Hierdoor moet een op zichzelf niet toegenomen hoeveelheid outlasting, over meer-
dere porties verdeeld, uitgescheiden worden. Dit gaat gepaard met imperatieve 
drang, leidend tot incontinentie voor outlasting. 
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APPENDIX I 
TDF formulas (according to Turesson and Notter, 67). 
For a course of frationated external irradiation: 
TDF = T-0.169 x (d.IOO)LSJS x N.J0-3 
For intracavitary irradiation at low dose rate: 
TDF = 2.02. (r x 100)1.35 T.J0-3 
In these formulas, the symbols used stand for: 
T = total treatment time of a course of external or intracavitary irradiation (in 
days). 
N = the number of fractions 
d the dose per fraction (in Gy) 
r the dose rate (in Gy 124 hr.). 
The acute doses at high dose rate were converted according to the monogram of 
Shuttleworth and Fowler (35) into a number of fractions of 2.0 Gy and then a 
TDFvalue for these fractions was calculated. 
L-Q formulas. 
For the calculation of the L-Q value two factors are of importance: the tolerance 
dose and the choice of the a 1 I a 2 value. As tolerance dose, we have arbitrarily 
chosen 35 x 2.0 Gy for fractionated external irradiation and 65 Gy in 7 days for low 
dose rate continuous irradiation. 
The a 1 I a 2 ratio was based on the results of Barendsen (68) and Kal (69), namely, 
10 for early and 2.5 for late effects. The following formulas were used for the calcu-
lation of the L-Q percentage: 
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D (to!) ETD and RE = 1 + d for fractionated external irradiation 
RE a 1 I "'z 
resp. RE = I + for low dose rate intracavitary irradiation 
D = the dose per fraction (Gy) 
r = the dose rate (Gy/hr) 
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APPENDIX]] 
Beginning Midway End 
of the radiotherapy course 
Serum bile acids X X X 
Faecal excr. of 
labeled bile acids X X 
Total daily 
faecal weight X X 
Transit time X X 
Continence test X 
Diet history X 
Time schedule for the different tests for intestinal function. 
6 weeks 6 months 
after after 
completion of the 
radiotherapy 
X X 
X X 
X X 
X X 
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APPENDIX III 
Scoring system for the diet history. 
Protein 
Fat 
I = I g/kg body weight ± I 0"7o 
2 = < 10% 
3 > 50"7o 
I = 30% - 35% 
2 = < 30% 
3 > 35% 
Carbohydrates I = > !50 g - < 60 cal. "7o 
2 = < !50 g 
Vitamins 
Minerals 
Fe 
Ca 
Free sugar 
Fibres 
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3 > 60 cal. "7o 
= normal 
2 = < 15% 
I = normal 
2 = < 10 mg 
I = normal 
2=<800mg 
1=20-25g 
3=>25g 
I = 3 slices of brown bread + I portion of vegetables + I 
portion of fruit 
2 = < I 
3 = > I 
Milk 1=\4-Yzl 
I = norm 
2 = lower 
3 = higher 
2=<\41 
3=Yzlor> 
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APPENDIX IV 
QUESTIONS CONCERNING THE DEFEACATION PATTERN 
I. How often do you have a bowel movement? 
a) not every day 
b) once each day 
c) twice each day 
d) more times per day 
2. Is it normal for you to have 5 or more bowel movements per day? 
a) yes 
b) no 
3. Is this 
a) less often 
b) as often 
c) more often 
than before you were irradiated? 
4. Are you sometimes troubled by abdominal cramps? 
a) yes 
b) no 
5. If you have answered "yes"' to the above, how often do you have trouble and 
are there perhaps circumstances which cause the abdominal cramps? 
6. Did you have troubles with abdominal cramps before you were irradiated? 
a) yes 
b) no 
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7. What is the nature of the stool? 
a) hard/marble-like 
b) normal/thick/well-formed 
c) pulpy 
d) liquid/waterthin 
8. AB compared with your stools before the irradiation, is your bowel movement 
now: 
a) harder 
b) not changed 
c) pulpy, but varying 
d) continuous diarrhea 
9. Can you postpone your bowel movements? 
a) yes, under all circumstances 
b) yes, with difficulty 
c) I must always rush to the toilet 
d) I am unable to postpone it 
10. Has your capacity to postpone defecation 
a) improved 
b) worsened 
after the irradiation? 
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APPENDIX V 
MEDIAN VALUES AND INTERQUARTILE RANGES 
Fasting Postprandial p.p.i. 
B 2.25 4.99 2.5 
1.5-3.4 3.5-6.9 1.1-4.2 
H 2.11 4.10 1.7 
1.4-3.0 3.0-5.2 0.9-2.9 
E 2.35 4.19 1.5 
1.7-3.4 3.0-5.5 0.4-2.8 
p 2.71 4.93 2.1 
I. 7-3.9 3.7-6.3 1.1-3.4 
c 2.65 4.75 1.6 
1.9-4.2 3.4-6.6 0.3-3.5 
Serial serum bile acid levels during pelvic radiotherapy. Fasting. 2-hour postprandial and postprandial in-
crease (p.p.i.) at different times during and after irradiation. 
(B = before RT: H = midway RT: E = end RT: P = 6 weeks after RT: C = 6 months after RT). 
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APPENDIX VI 
DIET HISTORY (n = 155) 
Score Norm Lower Higher 
Protein 123 32 
Fat 26 3 126 
Carbohydrates 127 28 
Vitamins 59 96 
Minerals 62 93 
Free sugars 40 115 
Fibres 41 72 
Milk 41 113 
Results of the food analysis as obtained by scoring of the diet history prior to the staft of radiotherapy. 
The number of patients in each scoring group for all food components are given. 
(For scoring system, see Appendix III). 
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APPENDIX VII 
Total leaked FAECAL CONTINENCE SCORES 
volume (ml) (0 = no problems, 4 = incontinence) 
0 1 2 3 4 
0 - 300 6 5 4 3 1 
300- 600 1 1 1 2 
600- 900 2 1 1 2 1 
900- 1200 10 1 6 4 2 
1200- 1500 12 2 5 4 7 
The relation between the faecal continence score as reported in the questionnaire (appendix IV) in patients 
compared to the total leaked volume during the rectal retention test according to Read (81) performed be-
fore irradiation. A small leaked volume indicates good continence. The number of patients for each 
combination of test result and continence score is given. No relation between the test results and the 
reported faecal continence during follow-up was found. 
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Still round the corner there may wait 
A new road or a secret gate; 
And though I oft have passed them by 
A day will come at last when I 
Shall take the hidden paths that run 
West of the Moon, East of the Sun. 
Maar om de hoek wacht ons misschien 
Een weg, een poort nag nooit gezien 
Hoewel 'k er vaak fangs ben gegaan 
Komt eens de dag dat ik zal gaan 
Verborgen paden, ondoorgrond 
Die /open tussen Maan en Zan. 
J.R.R. Tolkien 
(uit "the lord of 
the rings"). 
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